<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Escitalopram: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Escitalopram: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Escitalopram: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12430" href="/d/html/12430.html" rel="external">see "Escitalopram: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13043" href="/d/html/13043.html" rel="external">see "Escitalopram: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708748"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidal thoughts and behaviors</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors. Escitalopram is not approved for use in pediatric patients &lt;7 years of age.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F166813"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lexapro</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866781"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Escitalopram;</li>
<li>ACT Escitalopram ODT;</li>
<li>AG-Escitalopram;</li>
<li>APO-Escitalopram;</li>
<li>Auro-Escitalopram;</li>
<li>BIO-Escitalopram;</li>
<li>Cipralex;</li>
<li>JAMP-Escitalopram;</li>
<li>KYE-Escitalopram;</li>
<li>M-Escitalopram;</li>
<li>Mar-Escitalopram;</li>
<li>MINT-Escitalopram;</li>
<li>MYLAN-Escitalopram;</li>
<li>NAT-Escitalopram;</li>
<li>NRA-Escitalopram;</li>
<li>PMS-Escitalopram;</li>
<li>PMSC-Escitalopram;</li>
<li>RIVA-Escitalopram;</li>
<li>SANDOZ Escitalopram;</li>
<li>TARO-Escitalopram;</li>
<li>TEVA-Escitalopram</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F166832"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidepressant, Selective Serotonin Reuptake Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F166816"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Some experts suggest lower starting doses of 5 mg/day and lower titration increments of 5 mg, particularly in patients with anxiety who are sensitive to antidepressant-associated overstimulation effects (eg, anxiety, insomnia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1','lexi-content-ref-35900161'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d98a9598-5db0-4f0c-a3c4-96cdecc00d76">Binge eating disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Binge eating disorder (off-label use):</b>
<b>Oral:</b> Initial: 10 mg once daily; may increase daily dose based on response and tolerability in 10 mg increments at intervals ≥1 week up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18058852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18058852'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88be5c8f-c670-41f5-94ab-670c50aba438">Body dysmorphic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Body dysmorphic disorder (off-label use):</b>
<b>Oral:</b> Initial: 10 mg once daily; may increase daily dose gradually based upon response and tolerability in increments of 10 mg at intervals of every 2 to 3 weeks to 30 mg/day by week 6 to 10 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27056606','lexi-content-ref-Phillips.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27056606','lexi-content-ref-Phillips.1'])">Ref</a></span>). Some experts suggest usual doses of 40 mg/day and that in some patients for optimal response doses up to 60 mg/day may be necessary; however, ECGs are recommended at every 10 mg dosing increment above 30 mg/day (eg, at 40 mg/day, 50 mg/day, 60 mg/day) and then as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Phillips.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Phillips.1'])">Ref</a></span>). <b>Note:</b> An adequate trial for assessment of effect in BDD is 12 to 16 weeks, including maximum tolerated doses for at least 3 to 4 of those weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Phillips.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Phillips.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09d5012d-4c68-41f6-9a1f-54da08b78eeb">Bulimia nervosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bulimia nervosa (alternative agent) (off-label use):</b>
<b>Oral:</b> Initial: 10 mg once daily; may increase daily dose based on response and tolerability in increments of 10 mg at intervals ≥1 week. Maximum dose: 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Crow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Crow.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder: Oral:</b> Initial: 10 mg once daily; daily dose may be increased after ≥1 week based on response and tolerability to a maximum of 20 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar): Oral:</b> Initial: 10 mg once daily; daily dose may be increased in 10 mg increments after ≥1 week based on response and tolerability up to a maximum dose of 20 mg once daily (according to the manufacturer's labeling); however, doses up to 30 mg/day are used in practice and may provide further benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21410960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21410960'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder (OCD) (off-label use):</b>
<b>Oral:</b> Initial: 10 mg once daily; daily dose may be increased in 10 mg increments at intervals ≥1 week up to 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17240120','lexi-content-ref-21829108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17240120','lexi-content-ref-21829108'])">Ref</a></span>). Higher doses up to ~60 mg/day have been evaluated in open-label trials and may be considered in refractory patients; however, adverse effects may be increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18090508','lexi-content-ref-21829108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18090508','lexi-content-ref-21829108'])">Ref</a></span>). <b>Note:</b> An adequate trial for assessment of effect in OCD is considered to be ≥6 weeks at maximum tolerated dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27249090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27249090'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35322c81-c95a-4c47-baaf-72001a1c63ee">Panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder (off-label use):</b>
<b>Oral:</b> Initial: 5 mg once daily for 3 to 7 days, then increase dose to 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.3','lexi-content-ref-14658946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.3','lexi-content-ref-14658946'])">Ref</a></span>). May further increase daily dose at intervals ≥1 week to 20 mg once daily based on response and tolerability; mean dose in a clinical trial was ~10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14658946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14658946'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33aa39f3-80b9-497a-8725-78dfd54c167a">Posttraumatic stress disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttraumatic stress disorder (off-label use):</b>
<b>Oral:</b> Initial: 10 mg once daily; may gradually increase daily dose (4-week intervals used in some trials) based on response and tolerability up to 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27977469','lexi-content-ref-17107242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27977469','lexi-content-ref-17107242'])">Ref</a></span>). Some experts suggest dose titrations of 5 to 10 mg increments every 1 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03008e1c-e898-491f-b522-256bb5260378">Premature ejaculation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premature ejaculation (off-label use):</b>
<b>Oral:</b> Initial: 10 mg once daily; may increase daily dose based on response and tolerability at intervals of ~3 to 4 weeks up to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khera.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khera.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c36dd6b3-72d8-44c0-9113-9b954af8885b">Premenstrual dysphoric disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premenstrual dysphoric disorder (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Continuous daily dosing regimen:</i></b>
<b>Oral:</b> Initial: 5 to 10 mg once daily; over the first month, may increase dose based on response and tolerability to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Intermittent regimens:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Luteal phase dosing regimen: <b>Oral:</b> 5 to 10 mg once daily during the luteal phase of menstrual cycle (beginning therapy 14 days before anticipated onset of menstruation and continued to the onset of menses); over the first month, may increase dose to 20 mg once daily during the luteal phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2018','lexi-content-ref-15960573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2018','lexi-content-ref-15960573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Symptom-onset dosing regimen: <b>Oral:</b> 5 to 10 mg once daily from the day of symptom-onset until a few days after the start of menses; over the first month, may increase dose based on response and tolerability to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2018','lexi-content-ref-15960573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2018','lexi-content-ref-15960573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder (off-label use): Oral: </b>Initial: 5 to 10 mg once daily; may increase up to 20 mg once daily after ≥4 weeks based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15738503','lexi-content-ref-15274173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15738503','lexi-content-ref-15274173'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Nonhormonal alternative in patients unable or unwilling to take estrogen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22193145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22193145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 mg once daily, increase daily dose to 20 mg once daily after 4 weeks if symptoms not adequately controlled (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22480818','lexi-content-ref-21245182','lexi-content-ref-26382310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22480818','lexi-content-ref-21245182','lexi-content-ref-26382310'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Discontinuation of therapy:</b></i> When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include prior history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Switching</b>
<b> antidepressants:</b></i>Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from a monoamine oxidase inhibitor (MAOI). A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, and pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of escitalopram.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing escitalopram and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990631"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> No escitalopram-specific pharmacokinetic evaluations have been conducted. The following recommendation are inferred from citalopram pharmacokinetic information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9681666','lexi-content-ref-11214779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9681666','lexi-content-ref-11214779'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥20 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Initial: 5 mg once daily; gradually titrate based on tolerability and response with close monitoring for adverse effects (eg, QT prolongation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9681666','lexi-content-ref-11214779','lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9681666','lexi-content-ref-11214779','lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Neither citalopram nor its active metabolite, desmethylcitalopram, are significantly dialyzed (1% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11214779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11214779'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An increase in sudden cardiac death in hemodialysis patients prescribed selective serotonin reuptake inhibitors (SSRIs) with higher QT-prolonging potential (citalopram, escitalopram) compared to SSRIs with lower QT-prolonging potential was observed in a retrospective cohort study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30885935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30885935'])">Ref</a></span>). Therefore, use of an SSRI with a lower QT-prolonging potential may be preferred.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 5 mg once daily; gradually titrate based on tolerability and response with close monitoring for adverse effects (eg, QT prolongation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-11214779','lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-11214779','lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Unlikely to be significantly dialyzed (highly protein bound, large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An increase in sudden cardiac death in <i>hemodialysis</i> patients prescribed SSRIs with higher QT-prolonging potential (citalopram, escitalopram) compared to SSRIs with lower QT-prolonging potential was observed in a retrospective cohort study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30885935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30885935'])">Ref</a></span>). A similar risk has not been observed in patients on peritoneal dialysis (has not been studied), but use of an SSRI with a lower QT-prolonging potential may be preferred.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 5 mg once daily; gradually titrate based on tolerability and response with close monitoring for adverse effects (eg, QT prolongation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-Export.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987618"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b>Escitalopram's AUC increased 69% in patients with Child-Turcotte-Pugh class B liver impairment in a single-dose pharmacokinetic trial with no serious adverse events reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16584121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16584121'])">Ref</a></span>). <b>Dosing: </b>Accumulation in cirrhosis can be expected with repeat dosing; dosing recommendations are based on the known escitalopram pharmacokinetics, tolerability, toxicology, and dosage form availability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16584121','lexi-content-ref-25175904','lexi-content-ref-20170390','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16584121','lexi-content-ref-25175904','lexi-content-ref-20170390','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class A to C: Oral: </b>Initial: 5 mg once daily; may increase daily dose gradually based on response and tolerability in increments of 5 to 10 mg at intervals of ≥2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16584121','lexi-content-ref-25248846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16584121','lexi-content-ref-25248846'])">Ref</a></span>), not to exceed the usual indication-specific maximum recommended dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Worsening liver disease (eg, progression from baseline to a more severe Child-Pugh class):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Outpatient management:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>From baseline to Child-Turcotte-Pugh class A to C: </b>No dosage adjustment necessary (eg, maintain current dose) if tolerating; if suspecting intolerance, then reduce dose; not to exceed the usual indication-specific maximum recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Inpatient management: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Child-Turcotte-Pugh class A to C:</b> No dosage adjustment necessary (eg, maintain current dose) if tolerating; if suspecting intolerance, then reduce dose; not to exceed the usual indication-specific maximum recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F166817"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder; major depressive disorder (unipolar):</b>
<b>Oral:</b> 10 mg once daily; lower initial doses of 5 mg once daily have been suggested for depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VaDoD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VaDoD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy:</b></i> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Switching antidepressants:</b></i> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F7689783"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13043" href="/d/html/13043.html" rel="external">see "Escitalopram: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="55221b23-df1e-4634-930b-c53263f37bd6">Generalized anxiety disorder, social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder, social anxiety disorder (SAD):</b> Limited data available for SAD:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In pediatric patients, selective serotonin reuptake inhibitor (SSRI) therapy is considered first-line pharmacologic treatment for moderate to severe anxiety disorders in combination with cognitive behavioral therapy (CBT); a preferred SSRI has not been defined; therapeutic selection should be based on pharmacokinetic and pharmacodynamic data, patient tolerability, cost, and unique risks/precautions with specific agents (eg, QT prolongation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents &lt;18 years: Oral: Initial: 10 mg once daily; may then increase after 2 weeks by 5 or 10 mg/day if needed, based on clinical response and tolerability; maximum dose: 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18315447','lexi-content-ref-32857933','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18315447','lexi-content-ref-32857933','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder:</b>
<b>Note: </b>In the management of depression in children and adolescents, if pharmacotherapy deemed necessary with/without psychotherapeutic interventions, a selective serotonin reuptake inhibitor (SSRI) should be used first line; escitalopram is an alternative SSRI option for patients for whom fluoxetine is not an option (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2019','lexi-content-ref-23881712','lexi-content-ref-29483201','lexi-content-ref-31577402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2019','lexi-content-ref-23881712','lexi-content-ref-29483201','lexi-content-ref-31577402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Initial: 10 mg once daily; may be increased to 20 mg/day after at least 3 weeks if needed; maximum daily dose: 20 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Consider planning antidepressant discontinuation for lower-stress times, recognizing non-illness-related factors could cause stress or anxiety and be misattributed to antidepressant discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29337001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29337001'])">Ref</a></span>). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antidepressants:</b> Evidence for ideal selective serotonin reuptake inhibitor (SSRI) switching strategies in pediatric patients is sparse; strategies described in pediatric guidelines include a conservative approach (tapering and discontinuing the first SSRI before adding the second) and cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant). While consensus does not exist regarding which approach to utilize, it is important to note that the conservative approach runs the risk for exacerbation of symptoms or discontinuation syndrome; cross-titration may avoid these risks. Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches but is contraindicated when switching to or from a monoamine oxidase inhibitor. While not as common of a strategy, a direct switch may be considered when switching to another agent in the same or similar class (eg, when switching between 2 SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23879318','lexi-content-ref-23459282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23879318','lexi-content-ref-23459282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108714"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥7 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: CrCl &lt;20 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51108715"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥7 years and Adolescents: Oral: Maximum daily dose: 10 mg/<b>day</b> (level of hepatic dysfunction not defined).</p></div>
<div class="block arsc drugH1Div" id="F54469432"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent <b>mania</b> or <b>hypomania</b> in patients with unipolar major depressive disorder (MDD) have been reported, as many cases of bipolar disorder present in episodes of MDD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; a systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy, but not thereafter (up to 4.6 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>). In case reports involving escitalopram, treatment-emergent mania typically emerged in the first few months of treatment initiation and subsequent upward titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14719616','lexi-content-ref-15504660','lexi-content-ref-19629025','lexi-content-ref-30147322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14719616','lexi-content-ref-15504660','lexi-content-ref-19629025','lexi-content-ref-30147322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants. Multiple observational studies have found an association with SSRI use and a variety of bleeding complications, ranging from bruising, hematomas, petechiae, purpuric disease, and <b>epistaxis</b> to <b>cerebrovascular accident</b>, upper GI bleeding (UGIB), intracranial hemorrhage<b>, </b>postpartum hemorrhage, and perioperative bleeding, although conflicting evidence also exists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23699725','lexi-content-ref-30081645','lexi-content-ref-29536379','lexi-content-ref-28577352','lexi-content-ref-24314591','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-27834194','lexi-content-ref-28766108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23699725','lexi-content-ref-30081645','lexi-content-ref-29536379','lexi-content-ref-28577352','lexi-content-ref-24314591','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-27834194','lexi-content-ref-28766108'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly via inhibition of serotonin-mediated platelet activation (inhibition of the serotonin reuptake transporter) and subsequent platelet dysfunction. SSRIs may also increase gastric acidity, which can increase the risk of GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; bleeding risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>), although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory drugs (NSAIDs). For UGIB, some studies have found risk to be the highest in the first 28 to 30 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19716436','lexi-content-ref-19491861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19716436','lexi-content-ref-19491861'])">Ref</a></span>), whereas another study reported a median time of onset of 25 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17919277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17919277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of anticoagulants and/or antiplatelets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21948719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21948719'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-17506225'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of NSAIDs increases the risk for UGIB (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fragility fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited data from observational studies involving mostly older adults (≥50 years of age) suggest selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of <b>bone fractures</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774','lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406','lexi-content-ref-30964616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774','lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406','lexi-content-ref-30964616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; mechanism not fully elucidated; postulated to be through a direct effect by SSRIs on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406','lexi-content-ref-30775508'])">Ref</a></span>). An increased tendency to fall may also contribute to the increased risk of fractures associated with SSRIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22638709','lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22638709','lexi-content-ref-18219438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; risk appears to increase after initiation and may continue to increase with long-term use. A meta-analysis found risk of fracture increased from 2.9% over 1 year to 5.4% over 2 years; within 5 years, risk increased to 13.4% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term use may be a risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are associated with syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>) and/or <b>hyponatremia</b>, including severe cases, predominantly in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17202465','lexi-content-ref-25262043','lexi-content-ref-27773479','lexi-content-ref-17239054','lexi-content-ref-16896026','lexi-content-ref-30254775','lexi-content-ref-29302568']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17202465','lexi-content-ref-25262043','lexi-content-ref-27773479','lexi-content-ref-17239054','lexi-content-ref-16896026','lexi-content-ref-30254775','lexi-content-ref-29302568'])">Ref</a></span>). Hyponatremia is reversible with discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8804257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8804257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May cause SIADH via release of antidiuretic hormone (ADH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; usually develops within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower baseline serum sodium concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of hyponatremia (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Symptoms of psychosis (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are associated with <b>acute angle-closure glaucoma </b>(AACG) in case reports and a case-control study. AACG may cause symptoms including eye pain, <b>visual disturbance</b>, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27660499','lexi-content-ref-27993931','lexi-content-ref-16765693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27660499','lexi-content-ref-27993931','lexi-content-ref-16765693'])">Ref</a></span>). In addition, SSRIs may be associated with an increased risk of cataract development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28342338','lexi-content-ref-24631758']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28342338','lexi-content-ref-24631758'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> AACG: Unclear; hypothesized SSRIs may increase the intraocular pressure via serotonergic effects on ciliary body muscle activation and pupil dilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27135704','lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27135704','lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For AACG:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• ≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dose-dependent <b>prolonged QT interval on ECG </b>has been reported with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24259697','lexi-content-ref-23422053','lexi-content-ref-25619672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24259697','lexi-content-ref-23422053','lexi-content-ref-25619672'])">Ref</a></span>), including postmarketing reports of <b>torsades de pointes</b> (TdP); however, data are inconsistent on its effect on the QTc interval and its clinical significance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29275963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29275963'])">Ref</a></span>). One meta-analysis observed an increase in the QTc by an average of 7.3 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24922496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24922496'])">Ref</a></span>), while another study found an increase of only 3.5 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23928296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23928296'])">Ref</a></span>). Of note, citalopram is associated with a greater effect on QTc prolongation (mean QTc increase 7.8 ms [10 to 20 mg citalopram] and 10.3 ms [20 to 40 mg citalopram]) compared to escitalopram, the S-enantiomer of citalopram (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23360890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23360890'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; escitalopram is believed to cause QTc prolongation via direct blockade of rapid potassium delayed rectifier current (IKr), the delayed potassium rectifier current, encoded by the human ether-à-go-go-related gene (hERG) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24922496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24922496'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QT prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QT prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25356302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25356302'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported and typically occurs with coadministration of multiple serotonergic drugs but can occur following a single serotonergic agent at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28784915','lexi-content-ref-17426664','lexi-content-ref-21189920','lexi-content-ref-26491328','lexi-content-ref-27004312','lexi-content-ref-30844852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28784915','lexi-content-ref-17426664','lexi-content-ref-21189920','lexi-content-ref-26491328','lexi-content-ref-27004312','lexi-content-ref-30844852'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake and/or impair serotonin metabolism (eg, monoamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are commonly associated with sexual dysfunction in both men and women. The following adverse reactions have been associated with SSRI use: <b>Ejaculatory disorder</b> (primarily ejaculatory delay), <b>orgasm disturbance</b>, <b>erectile dysfunction</b>, <b>decreased libido</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16841623','lexi-content-ref-15046541','lexi-content-ref-29955469','lexi-content-ref-32048624','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16841623','lexi-content-ref-15046541','lexi-content-ref-29955469','lexi-content-ref-32048624','lexi-content-ref-26003261'])">Ref</a></span>). <b>Priapism</b> and decreased penile sensation have also been reported with SSRIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30867630','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30867630','lexi-content-ref-26003261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Increases in serotonin may affect other hormones and neurotransmitters involved in sexual function; in particular, testosterone's effect on sexual arousal and dopamine's role in achieving orgasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-10333979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-10333979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (sexual dysfunction is commonly associated with depression; SSRI-associated sexual dysfunction may be difficult to differentiate in treated patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12243609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12243609'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of <b>suicidal ideation</b> and <b>suicidal tendencies</b> in pediatric and young adult patients (18 to 24 years of age) in short-term studies. In adults &gt;24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231','lexi-content-ref-31318184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231','lexi-content-ref-31318184'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to long-term use (ie, &gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome</b>, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, ‘shock-like’ sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability, mania) have been reported, primarily following abrupt discontinuation. Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24847997','lexi-content-ref-25721705','lexi-content-ref-15906018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24847997','lexi-content-ref-25721705','lexi-content-ref-15906018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the selective serotonin reuptake inhibitor (SSRI). Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420','lexi-content-ref-23596418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420','lexi-content-ref-23596418'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019','lexi-content-ref-15906018','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019','lexi-content-ref-15906018','lexi-content-ref-25677972'])">Ref</a></span>) .</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F166780"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (6% to 14%), nausea (15% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculatory disorder (9% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Escitalopram: Adverse Reaction: Ejaculatory Disorder table link" class="lexi-table-link" data-table-id="lexi-content-escitalopram-adverse-reaction-ejaculatory-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-escitalopram-adverse-reaction-ejaculatory-disorder')">table 1</a>)</span><span class="table-link" style="display:none;">Escitalopram: Adverse Reaction: Ejaculatory Disorder</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Escitalopram: Adverse Reaction: Ejaculatory Disorder" frame="border" id="lexi-content-escitalopram-adverse-reaction-ejaculatory-disorder" rules="all">
<caption style="text-align:center;">
<b>Escitalopram: Adverse Reaction: Ejaculatory Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Escitalopram)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Escitalopram)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Generalized anxiety disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">195</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Major depressive disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">225</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">188</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (4% to 13%; literature suggests incidence is lower in children and adolescents compared to adults [Safer 2006]), headache (24%), insomnia (7% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (3% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Escitalopram: Adverse Reaction: Decreased Libido table link" class="lexi-table-link" data-table-id="lexi-content-escitalopram-adverse-reaction-decreased-libido" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-escitalopram-adverse-reaction-decreased-libido')">table 2</a>)</span><span class="table-link" style="display:none;">Escitalopram: Adverse Reaction: Decreased Libido</span>, menstrual disease (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Escitalopram: Adverse Reaction: Decreased Libido" frame="border" id="lexi-content-escitalopram-adverse-reaction-decreased-libido" rules="all">
<caption style="text-align:center;">
<b>Escitalopram: Adverse Reaction: Decreased Libido</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Escitalopram)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Escitalopram)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Generalized anxiety disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">429</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">427</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Major depressive disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">715</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">592</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (children and adolescents: 3%), abdominal pain (2%), constipation (3% to 6%), decreased appetite (3%), dyspepsia (2% to 6%), flatulence (2%), vomiting (3%; literature suggests incidence is higher in adolescents compared to adults, and is two- to threefold higher in children compared to adolescents [Safer 2006]), xerostomia (4% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anorgasmia (2% to 6%), erectile dysfunction (3%)<span class="lexi-table-link-container"> (<a aria-label="Escitalopram: Adverse Reaction: Erectile Dysfunction table link" class="lexi-table-link" data-table-id="lexi-content-escitalopram-adverse-reaction-erectile-dysfunction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-escitalopram-adverse-reaction-erectile-dysfunction')">table 3</a>)</span><span class="table-link" style="display:none;">Escitalopram: Adverse Reaction: Erectile Dysfunction</span>, urinary tract infection (children and adolescents: ≥2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Escitalopram: Adverse Reaction: Erectile Dysfunction" frame="border" id="lexi-content-escitalopram-adverse-reaction-erectile-dysfunction" rules="all">
<caption style="text-align:center;">
<b>Escitalopram: Adverse Reaction: Erectile Dysfunction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Escitalopram)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Escitalopram)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">225</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">188</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (3%), dizziness (3% to 7%), fatigue (2% to 8%), irritability (≤2%), lethargy (3%), outbursts of anger (children and adolescents: 2%), paresthesia (2%), yawning (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (children and adolescents: ≥2%), neck pain (≤3%), shoulder pain (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (5%), nasal congestion (children and adolescents: ≥2%), nasopharyngitis (children and adolescents: 3%), rhinitis (5%), sinusitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, hypertension, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, gastroenteritis, heartburn, increased appetite</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Lack of concentration, migraine</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, jaw tightness, limb pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, cough, paranasal sinus congestion, sinus headache</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation, bradycardia, deep vein thrombosis, edema, flushing, heart failure, hypertensive crisis, hypotension, orthostatic hypotension, phlebitis, prolonged QT interval on ECG (Funk 2013), pulmonary embolism, syncope, tachycardia, thrombosis, torsades de pointes (Kumar 2020), ventricular arrhythmia, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Etminan 2018), dermatitis, ecchymoses, erythema multiforme, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus, galactorrhea not associated with childbirth (Pathania 2018), heavy menstrual bleeding, hypercholesterolemia, hyperglycemia, hyperprolactinemia, hypoglycemia, hypokalemia, hyponatremia (literature suggests incidence of hyponatremia among SSRIs ranges from &lt;1% to as high as 32% [Jacob 2006; Rawal 2017]), SIADH (Raj 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia, gastroesophageal reflux disease, gastrointestinal hemorrhage (Kumar 2009), pancreatitis, rectal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal orgasm, abnormal uterine bleeding (postmenopausal) (Yadav 2022), dysuria, mastalgia (Pathania 2018), priapism (Budzak 2019), sexual disorder (Roy 2019), spontaneous abortion, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia, aplastic anemia, hemolytic anemia, hypoprothrombinemia, immune thrombocytopenia, increased INR, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatic necrosis, hepatitis (including cholestatic hepatitis) (Wabont 2022), increased liver enzymes, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Conde 2022), drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, aggressive behavior, agitated depression, akathisia (Arshad 2022), amnesia, anosmia (including hyposmia), apathy, asthenia, ataxia, cerebrovascular accident (Douros 2018), choreoathetosis, delirium, delusion, depersonalization, extrapyramidal reaction, falling, hallucination, hyperactive behavior (including agitation, hyperkinetic muscle activity, and restlessness occurring in children at a two- to threefold higher incidence compared to adolescents; it is more prevalent in adolescents compared to adults) (Safer 2006), hypoesthesia, hypomania (Sharma 2009b), malaise, mania (Prapotnik 2004), myasthenia, myoclonus, nervousness, neuroleptic malignant syndrome (Stevens 2008), nightmares, panic, paranoid ideation, parkinsonism, psychosis, restless leg syndrome, seizure, serotonin syndrome (Huska 2007; Sanyal 2010), suicidal ideation (Madsen 2019), suicidal tendencies, tremor, vertigo, withdrawal syndrome (De Berardis 2014; Fava 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (fragility) (Khanassov 2018), dyskinesia, dystonia, rhabdomyolysis, tardive dyskinesia (Fischer 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (AlQuorain 2016; Zelefsky 2006), diplopia, mydriasis, nystagmus disorder, subconjunctival hemorrhage (Sharma 2009a), visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, epistaxis (Lake 2000)</p></div>
<div class="block coi drugH1Div" id="F166795"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to escitalopram, citalopram, or any component of the formulation; use of monoamine oxidase (MAO) inhibitors (concurrently or within 14 days of discontinuing either escitalopram or the MAO inhibitor); initiation of escitalopram in a patient receiving linezolid or intravenous methylene blue; concurrent use of pimozide.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Known QT-interval prolongation or congenital long QT syndrome</p></div>
<div class="block war drugH1Div" id="F166778"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Patients with a recent history of MI or unstable heart disease were excluded from clinical trials; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and half-life and plasma concentrations are increased. However, selective serotonin reuptake inhibitors such as escitalopram are considered the safest antidepressants to use in chronic liver disease because of their relative lack of side effects and high therapeutic index (Mauri 2014; Mullish 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic disease: Use with caution; limited data in patients with altered metabolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment; dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C19 poor metabolizers: Escitalopram systemic exposure may be increased in CYP2C19 poor metabolizers.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Bioavailability and half-life are increased by 50% in older adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878447"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F166789"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (10 mL [DSC], 240 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lexapro: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lexapro: 10 mg, 20 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F166775"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F166798"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Escitalopram Oxalate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.79 - $2.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Escitalopram Oxalate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $4.14 - $4.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $4.33 - $4.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $4.51 - $4.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lexapro Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $16.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $17.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $18.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866782"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cipralex: 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 15 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p></div>
<div class="block adm drugH1Div" id="F166792"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer once daily (morning or evening), with or without food.</p></div>
<div class="block admp drugH1Div" id="F52612723"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer once daily (morning or evening); may be administered with or without food.</p></div>
<div class="block meg drugH1Div" id="F7874431"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021323s057%2C021365s040lbl.pdf%23page%3D30&amp;token=6q8%2FFMnID%2FvLEn9KissxppZO1TP%2Fcbg7NEMbYFmdReMdwyt5Iy6%2BAcgy2YO0tJZ%2FkSRV6bB%2BxF04aF%2F7I40z0FyTJMFEELvJ%2B7ZGNPnQXPw1FRuBmYL%2BoK%2B2pVnIQDvN&amp;TOPIC_ID=9046" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021323s057,021365s040lbl.pdf#page=30</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F166790"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder:</b> Acute treatment of generalized anxiety disorder in adults and pediatric patients ≥7 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b> Acute and maintenance treatment of unipolar major depressive disorder in adults and pediatric patients ≥12 years of age.</p></div>
<div class="block off-label drugH1Div" id="F25475741"><span class="drugH1">Use: Off-Label: Adult</span><p>Binge eating disorder; Body dysmorphic disorder; Bulimia nervosa; Obsessive-compulsive disorder; Panic disorder; Posttraumatic stress disorder; Premature ejaculation; Premenstrual dysphoric disorder; Social anxiety disorder; Vasomotor symptoms associated with menopause</p></div>
<div class="block mst drugH1Div" id="F6052832"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Escitalopram may be confused with citalopram</p>
<p style="text-indent:-2em;margin-left:4em;">Lexapro may be confused with Loxitane [DSC]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Selective Serotonin Reuptake Inhibitors (SSRIs) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zavesca: Brand name for escitalopram [in multiple international markets; ISMP April 21, 2010], but also brand name for miglustat [Canada, US, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F166826"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F166782"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Selective Serotonin Reuptake Inhibitors may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the adverse/toxic effect of Escitalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Escitalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the antiplatelet effect of Escitalopram. Escitalopram may enhance the QTc-prolonging effect of Citalopram. Escitalopram may enhance the serotonergic effect of Citalopram. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May enhance the QTc-prolonging effect of Escitalopram. CloZAPine may enhance the serotonergic effect of Escitalopram. This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, serotonin syndrome, and neuroleptic malignant syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Escitalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Escitalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of DULoxetine. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of DULoxetine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of Escitalopram. Encorafenib may decrease the serum concentration of Escitalopram. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and reduced citalopram concentrations and efficacy when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole: May increase the serum concentration of Escitalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of Escitalopram. Fexinidazole may increase the serum concentration of Escitalopram. Management: Monitor for increased escitalopram toxicities (including increased QTc prolongation and serotonin syndrome) if combined with fexinidazole. Consider limiting the escitalopram dose to 10 mg daily when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: Escitalopram may enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Gepirone may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: Escitalopram may enhance the QTc-prolonging effect of Gilteritinib. Gilteritinib may diminish the therapeutic effect of Escitalopram.  Management: Avoid use of this combination if possible. If use is necessary, monitor for reduced response to escitalopram and for QTc prolongation and arrhythmias. Patients with other risk factors may be at greater risk for these serious toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Antidepressants (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol. Haloperidol may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: Escitalopram may enhance the hypoglycemic effect of Hydroxychloroquine. Hydroxychloroquine may enhance the QTc-prolonging effect of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the QTc-prolonging effect of Escitalopram. Escitalopram may enhance the QTc-prolonging effect of Lofexidine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: May increase the serum concentration of Escitalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Ondansetron may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation or serotonin syndrome may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Escitalopram. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): Escitalopram may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Escitalopram may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Antidepressants (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): QT-prolonging Antidepressants (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Escitalopram may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Escitalopram may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Rasagiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Use the lowest effective dose of SSRIs in patients treated with safinamide and monitor for signs and symptoms of serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of other Selective Serotonin Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of other Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Selegiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Serotonin/Norepinephrine Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and seizures when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the serotonergic effect of Escitalopram. Escitalopram may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Venlafaxine. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Venlafaxine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Escitalopram may enhance the QTc-prolonging effect of Voriconazole. Voriconazole may increase the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors. Vortioxetine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55514860"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Escitalopram is approved for the treatment of unipolar major depressive disorder. If treatment for major depressive disorder is initiated for the first time in a patient planning to become pregnant, escitalopram is not one of the preferred selective serotonin reuptake inhibitors (SSRIs) (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Escitalopram is also used off label for the treatment of premenstrual dysphoric disorder. For patients attempting to conceive, symptom onset dosing may be beneficial to minimize potential fetal exposure (Ismaili 2016; Lanza di Scalea 2019).</p>
<p style="text-indent:0em;margin-top:2em;">SSRIs may be associated with male and female treatment-emergent sexual dysfunction (Coskuner 2018; WFSBP [Bauer 2013]). Decreased libido and anorgasmia have been reported in females; ejaculation disorder, decreased libido, and impotence have been reported in males with escitalopram use. This may also be a manifestation of the psychiatric disorder. The actual risk associated with escitalopram is not known. SSRI-related sexual dysfunction may resolve with dose reduction or discontinuation of the SSRI; in some cases, sexual dysfunction may persist once therapy is discontinued (Coskuner 2018; Jing 2016; Waldinger 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Amenorrhea followed by a false positive urine pregnancy test was reported in a patient treated with escitalopram for premenstrual dysphoric disorder and panic disorder. After ~4 months of escitalopram treatment, she missed a period and took a home pregnancy test, which was positive. A serum pregnancy test was negative. Escitalopram was discontinued and menses resumed 2 weeks later (Selvaraj 2017).</p></div>
<div class="block pri drugH1Div" id="F166799"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Escitalopram and desmethylcitalopram cross the placenta and are distributed into the amniotic fluid (Loughhead 2006; Rampono 2009; Sit 2011).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, selective serotonin reuptake inhibitors (SSRIs) have been evaluated extensively in pregnant patients. Studies focusing on newborn outcomes following first trimester exposure often have inconsistent results due to differences in study design and confounders such as maternal disease and social factors (Anderson 2020; Biffi 2020; Fitton 2020; Reefhuis 2015; Womersley 2017). Adverse effects in the newborn following SSRI exposure late in the third trimester can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. Prolonged hospitalization, respiratory support, or tube feedings may be required. Symptoms may be due to the toxicity of the SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn has been reported with SSRI exposure; although the absolute risk is small, monitoring of infants exposed to SSRIs late in pregnancy is recommended (Masarwa 2019; Ng 2019). The long-term effects of in utero SSRI exposure on infant neurodevelopment and behavior are not known (CANMAT [MacQueen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of escitalopram may be altered, possibly due to CYP2C19 inhibition. However, changes are not likely to have clinical implications. Close clinical monitoring as pregnancy progresses is recommended to assist dose adjustment when needed (Schoretsanitis 2020).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment for major depressive disorder is initiated for the first time during pregnancy, escitalopram can be considered (CANMAT [MacQueen 2016]); however, if pregnancy occurs during treatment, escitalopram can be continued (Larsen 2015). Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants. Pregnant patients 18 to 45 years of age or their health care providers may contact the registry to enroll; enrollment should be done as early in pregnancy as possible (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/).</p></div>
<div class="block brc drugH1Div" id="F166800"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram and its desmethylcitalopram (DCT) metabolite are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of escitalopram has been calculated in review articles to be 3% to 6% of the weight adjusted maternal dose (Berle 2011; Orsolini 2015); RIDs up to 10.5% have also been located (Delaney 2018). In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000); however, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">In one review, the RID of escitalopram was calculated using pooled data from 12 mother/infant pairs providing an estimated daily infant dose via breast milk of 0.04 mg/day. The maternal dose and actual breast milk concentrations for the calculation were not provided (Berle 2011). A second review included information from 37 cases; maternal daily doses of escitalopram were 5 to 20 mg/day. The highest breast milk concentrations of escitalopram presented were 27 to 99 ng/mL from a study of 8 women 3 to 32 weeks postpartum, providing a RID of 5.3%; the DCT metabolite was also present in breast milk (Orsolini 2015). A study published since these reviews reports breast milk concentrations that are almost double following a maternal dose of escitalopram 30 mg/day. At this maternal dose, the peak escitalopram breast milk concentration was 202.2 ng/mL and the RID of escitalopram is 10.5%, providing an estimated daily infant dose via breast milk of 0.03 mg/kg/day. Metabolite concentrations were not evaluated (Delaney 2018). Although maternal genotype was not evaluated in these studies, a pharmacokinetic modeling study has demonstrated mothers who are poor metabolizers of CYP2C19 would have greater breast milk concentrations of escitalopram. The model predicts a median escitalopram RID of 5.7% in breastfed infants of mothers who are poor metabolizers compared to 3% for other phenotypes, following a maternal dose of escitalopram 5 to 20 mg/day (RID range 0.8% to 11.3% inclusive of all phenotypes) (Weisskopf 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">In one study, mean peak milk concentrations of escitalopram occurred ~5.5 hours after the maternal dose; the mean peak concentration of DCT was reported at ~4.8 hours (Rampono 2006). However, avoiding breastfeeding during the expected peak concentrations will generally not decrease infant exposure significantly for antidepressants with long half-lives (Berle 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Agitation, poor feeding, poor weight gain, restlessness, and excessive sedation have been reported in infants exposed to escitalopram via breast milk. Infants exposed to a selective serotonin reuptake inhibitor (SSRI) via breast milk should be monitored for irritability and changes in sleep, feeding patterns, and behavior, as well as growth and development (ABM [Sriraman 2015]; Sachs 2013; Weissman 2004; WFSBP [Bauer 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Maternal use of an SSRI during pregnancy may cause delayed lactogenesis (Marshall 2010); however, the underlying maternal illness may also influence this outcome (Grzeskowiak 2018). Untreated severe or chronic depression in the postpartum period also has negative effects on the mother (Slomian 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Psychotherapy or other nonmedication therapies are recommended for the initial treatment of mild depression in breastfeeding patients; antidepressant medication is recommended when psychotherapy is not an option or symptoms are moderate to severe. If a specific SSRI was used effectively during pregnancy, it can be continued while breastfeeding if no contraindications exist (ABM [Sriraman 2015]). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. When first initiating an antidepressant in a breastfeeding patient, agents other than escitalopram are preferred. Patients successfully treated with escitalopram during pregnancy may continue use while breastfeeding if there are no other contraindications (ABM [Sriraman 2015]; Larsen 2015).</p></div>
<div class="block mop drugH1Div" id="F166786"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ECG (in patients at increased risk for QT-prolonging effects); electrolytes (potassium and magnesium concentrations at baseline and as clinically indicated); liver and renal function tests (baseline; as clinically indicated); serum sodium in at-risk populations (as clinically indicated); CBC (as clinically indicated); screen all patients for any personal or family history of bipolar disorder, hypomania, or mania (prior to initiating therapy); closely monitor patients for depression, clinical worsening, suicidality, psychosis, or unusual changes in behavior (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania), particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); signs/symptoms of serotonin syndrome such as mental status changes (eg, agitation, hallucinations, delirium, coma), autonomic instability (eg, tachycardia, labile BP, diaphoresis), neuromuscular changes (eg, tremor, rigidity, myoclonus), GI symptoms (eg, nausea, vomiting, diarrhea), and/or seizures.</p></div>
<div class="block pha drugH1Div" id="F166777"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Escitalopram is the S-enantiomer of the racemic derivative citalopram, which selectively inhibits the reuptake of serotonin with little to no effect on norepinephrine or dopamine reuptake. It has no or very low affinity for 5-HT<sub>1-7</sub>, alpha- and beta-adrenergic, D<sub>1-5</sub>, H<sub>1-3</sub>, M<sub>1-5</sub>, and benzodiazepine receptors. Escitalopram does not bind to or has low affinity for Na<sup>+</sup>, K<sup>+</sup>, Cl<sup>-</sup>, and Ca<sup>++</sup> ion channels.</p></div>
<div class="block phk drugH1Div" id="F166794"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Anxiety disorders (generalized anxiety, obsessive-compulsive, panic, and posttraumatic stress disorder): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Issari 2016; Varigonda 2016; WFSBP [Bandelow 2023a]); some experts suggest up to 12 weeks of treatment may be necessary for response, particularly in patients with obsessive-compulsive disorder and posttraumatic stress disorder (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2023a]; WFSBP [Bandelow 2023b]).</p>
<p style="text-indent:-2em;margin-left:4em;">Body dysmorphic disorder: Initial effects may be observed within 2 weeks; some experts suggest up to 12 to 16 weeks of treatment may be necessary for response in some patients (Phillips 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009; Taylor 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Premenstrual dysphoric disorder: Initial effects may be observed within the first few days of treatment, with response at the first menstrual cycle of treatment (ISPMD [Nevatte 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~20 L/kg (Søgaard 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~56% to plasma proteins</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2C19 and 3A4 to S-desmethylcitalopram (S-DCT); S-DCT is metabolized to S-didesmethylcitalopram (S-DDCT) via CYP2D6; in vitro data suggest metabolites do not contribute significantly to the antidepressant effects of escitalopram</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 80%; tablets and oral solution are bioequivalent</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean: Adolescents: 19 hours; Adults: ~27 to 32 hours (increased ~50% in the elderly and doubled in patients with hepatic impairment)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Escitalopram: Adolescents: 2.9 hours; Adults: ~5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (8% as unchanged drug; S-DCT 10%)</p></div>
<div class="block phksp drugH1Div" id="F51154054"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: No data available for escitalopram. Citalopram clearance decreased by 17% in mild to moderate impairment. Limited information is available in patients with severe impairment (Joffe 1998; Spigset 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with mild and moderate hepatic impairment had a 51% and 69% increase in AUC, respectively. Additionally, the clearance/F of those with moderate impairment was 16 L/hour compared to a 25 L/hour clearance in healthy patients (Areberg 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC and half-life increased ~50%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F166802"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Asitalox | Cipralex | Cipralex Meltz | Citalo | Ecipharm | Entapro | Esil | Lexaprim | Tabupram | Xeforam</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aramix | Coverfax | Elevopram | Esciprox | Escitalopran teva | Lexapro | Nexdia | Novo humorap | Rempec | Rostalopram | Zenvas</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adescilan | Cipralex | Cipralex Meltz | Escitalopram +pharma | Escitalopram Accord | Escitalopram arcana | Escitalopram bluefish | Escitalopram easypharm | Escitalopram genericon | Escitalopram hexal | Escitalopram krka | Escitalopram ranbaxy | Escitalopram sandoz | Escitalopram stada | Pramulex | Solatcit</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo escitalopram | Apx escitalopram | Blooms the chemist escitalopram | Btc escitalopram | Chemmart Escitalopram | Cilopam s | Cipla escitalopram | Citlam s | Escicor | Escilex | Escipro | Escitalaccord | Escitalopram actavis | Escitalopram an | Escitalopram arx | Escitalopram as | Escitalopram b&amp;b | Escitalopram drla | Escitalopram ga | Escitalopram generichealth | Escitalopram gh | Escitalopram lapl | Escitalopram sandoz | Escitalopram str | Escitalopram wt | Esicor | Esipram | Esital | Esitalo | Espiram | Genrx escitalopram | Ipca escitalopram | Lexam | Lexapro | Loxalate | Noumed escitalopram | Pca escitalopram | Pharmacor escitalopram | Ppa escitalopram | Ppc escitalopram | Terry White Escitalopram</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acipam | Andepram | Citalex | Elodep | Escilex | Esipram | Expres | Losita | Meliva | Nexcital | Nexito | Oxapro | Seropam</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Escitaham EG | Escitalopram | Escitalopram apotex | Escitalopram eg | Escitalopram mylan | Escitalopram ratiopharm | Escitalopram sandoz | Escitalopram teva | Sipralexa | Talocimylan</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Cilentra</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alvocital | Cipralex | Elicea | Eloryqa | Escipram | Escitacon | Escitalon | Escitalopram Accord | Escitalopram teva | Escitasan | Escitil | Esoprex | Essobel | Lenuxin | Mersinol | Oroprex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Astrale | Deciprax | Eficentus | Esc | Esc odt | Escena | Escilex | Escip | Espran | Estalox | Eudok | Exodus | Felissa | Konecta | Lexaprass | Mind | Neuropram | Oxalato de escitalopram | Reconter | Remis | Sedopan | Serolex | Unitram | Vidapram</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Cipralex Meltz | Escitalopram actavis | Escitalopram axapharm | Escitalopram helvepharm | Escitalopram mepha | Escitalopram nobel | Escitalopram sandoz | Escitalopram spirig hc | Escitalopram viatris | Escitalopram zentiva | Escitax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Arel | Ecitalex ft | Escitalopram | Escitavitae | Ipran | Lexapro | Nexipram | Zepaz</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bai luo te | Bai shi ke | Lexapro</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bruliva | Cilopram | Decitapram | Ecitalex | Erliniz | Escitalopram | Escitalopram sandoz | Eslopran | Euthymin | Expogram | Flexocam | Ipca Cilopram | Ipran | Lexapro | Lexpram | Nexipram | Nexito | S Citap | Talopram</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Anxila | Apo escitalopram | Cipralex | Cipralex orotab | Depresinal | Despra | Elicea | Escirdec | Escitalopram | Escitalopram Accord | Escitalopram mylan | Escitalopram Orion | Escitalopram stada | Escitalopram teva | Escitil | Esoprex | Estan | Isozyloram | Itakem | Lenuxin | Miraklide | Purcema</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Escitalex | Escitalopram | Escitalopram actavis | Escitalopram al | Escitalopram aurobindo | Escitalopram axcount | Escitalopram axunio | Escitalopram basics | Escitalopram Beta | Escitalopram CT | Escitalopram delorbis | Escitalopram Glenmark | Escitalopram hec pharm | Escitalopram hetero | Escitalopram heumann | Escitalopram hexal | Escitalopram macleods | Escitalopram mylan | Escitalopram neuraxpharm | Escitalopram ratiopharm | Escitalopram stada | Escitalopram teva | Escitalopram zentiva | Seroplex</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Escivriens</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acropram | Benumor | Ec Pram | Educil | Es citopram | Escitalopram | Escitalopram mamey | Escitalopram sandoz | Eslopram | Eurodepres | Lexapro | Negadep | Neozentius | Parotin | Serofel | Tacilopram</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Animaxen | E-Zentius | Ecitalex ft | Erliniz | Esc | Escitalopram | Escitalopram mk | Escitavitae | Ezentius | Ipran | Lexapro | Novo humorap | Selective | Taloprax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Ciraset | Elicea | Escitalopram Accord | Escitalopram actavis | Escitalopram Portfarma | Escitalopram ratiopharm | Escitalopram sandoz | Escitalopram teva | Eslorex | Estan | Nepanil | Norestal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Atmecipia | Cipra pro | Cipralex | Ciprapro | Citalomep | Citapronex | Escita | Escitaloborg | Escitapram | Estikan | Excelsa | Futapramin | Hermpro | Nodep | Psychopram | Taloscito | Verdapiotal | Xyga rot</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Elicea | Escilan | Escimylan | Escitalopram Accord | Escitalopram actavis | Escitalopram almus | Escitalopram alter | Escitalopram amneal | Escitalopram apotex | Escitalopram aristo | Escitalopram Aurovitas | Escitalopram Bexal | Escitalopram bluefish | Escitalopram Cinfa | Escitalopram combix | Escitalopram Davur | Escitalopram flas cinfa | Escitalopram kern pharma | Escitalopram krka | Escitalopram mabo | Escitalopram macleods | Escitalopram Meiji | Escitalopram mylan | Escitalopram normon | Escitalopram pensa | Escitalopram qualigen | Escitalopram ranbaxy | Escitalopram ratiopharm | Escitalopram sandoz | Escitalopram stada | Escitalopram tarbis | Escitalopram Tecnigen | Escitalopram teva | Escitalopram ur | Escitalopram vegal | Escitalopram viso farmaceutica | Escitalopram zentiva | Esertia | Heipram | Mozarin flas</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Escitalopram sandoz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Debrelop | Escitalopram Accord | Escitalopram actavis | Escitalopram krka | Escitalopram lundbeck | Escitalopram navamedic | Escitalopram Orion | Escitalopram ratiopharm | Escitalopram sandoz | Escitalopram sanoswiss | Esipral</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Escitalopram abbott | Escitalopram almus | Escitalopram arrow | Escitalopram biogaran | Escitalopram cristers | Escitalopram eg | Escitalopram evolugen | Escitalopram krka | Escitalopram mylan | Escitalopram ranbaxy | Escitalopram sandoz | Escitalopram teva | Escitalopram zentiva | Escitalopram zydus | Seroplex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Escitalopram</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Enlift | Entact | Escitalopram | Escitalopram Generics | Escitalopram/actavis | Escitalopram/ariti | Escitalopram/mylan | Escitalopram/sandoz | Escitalopram/teva | Escopram | Eslorex | Espoza | Ratice | Tepram</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo escitalopram | Esitalo | Esopam | Lexapro | Oxapro | Pramokline | S oropram</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Citram | Elicea | Elicea q-tab | Escital | Escitalon | Escitalopram PharmaS | Serpentil | Zepira</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Cipralex Meltz | Escigen | Escitalopram actavis | Escitalopram Pharmaswiss | Escitalopram sandoz | Escitalopram teva | Escitalopram zentiva | Escitil | Isozyloram | Lanocipram | Nepanil | Scippa</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Depram | Elxion | Talox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Esciprex | Escitalopram | Escitalopram bluefish | Escitalopram krka | Escitalopram teva | Escitalpro | Etalopro | Lexapro</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Esto</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acopram | Alwel | Anxiset E | Articalm | Atpram | Atril | C-pram-s | Censpram | Cilapam | Cilentra | Cipam S | Cipralex | Cita S | Citaford s | Citajoy | Citalin | Citalop-s | Citapure | Citawok | Citel | Citofast | Citograph | Depitame | Deplam-s | Depranex | Deptune | Desilam | Dexanil | Dipwell | Ecinil | Ecitalop | Ecitelo | Elcit | Enzycare | Escigress | Escipix | Escipra | Esciptal | Escirise | Escitacalm | Escitalent | Escitapax | Escitlocad | Escitol | Escitus | Escizen | Escnx | Escytop | Esdep | Esiteo | Esitor | Esjoy | Esnax | Esok | Esopam | Esopram | Espam | Esram | Essita 5 | Esta | Estam | Estilo | Estomine | Eszen | Etilopram | Excita | Ezeepam | Feliz s | Firsito | Galop | Geripram | Halotil | Itcalms | Jolivel | Joycom | Lexadep | Lexatal | Monopram | Newcita | Nexito | Pocital s | Pramnix | Prasilex | Pridep s | Recita | Rexipra | S Citadelm | S Citadep | S-celepra | Sc-talo | Sri | Stalopam | Szetalo | Talo s | Taloprex | Taloz | Topdep-s | Xtaz | Yellowpam</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">E citalopram</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Amasci | Cipralex | Entact | Escertal | Escitalopram | Escitalopram Accord | Escitalopram aurobindo | Escitalopram doc | Escitalopram eg | Escitalopram krka | Escitalopram pensa | Escitalopram ranbaxy | Escitalopram sandoz | Escitalopram Tecnigen | Escitalopram teva | Escitalopram zentiva | Giachela | Mensoram | Prameffex | Sosecit</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Depralex | Exopex | Ezura | Purlex | Zelax | Zetaprix</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lexapro</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ascipram | Avestalo | Cipralex | Clomentin | Esitopam | Ezura | Feliz s | Nexito | Nodep</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cistal | Cital | Citalam | Citalo | Citaplex | Citapram | Citaprex | Citapril | Citapro | Depro | Easypram | Edpa | Escital | Escitalo | Escitalopram | Escitam | Espram | Estal | Estoram | Etalop | Exipram | Exipro | Expram | Ezpram | Hanwha escitalopram | Jepram | L xapam | Lecipram | Lexacold | Lexacure | Lexagen | Lexamin | Lexamo | Lexaone | Lexapam | Lexapram | Lexapro | Lexastar | Lexatin | Lexcitam | Lexipram | Lexital | Lexler | Lexpram | Lopram | Maxpra | Neocital | Newpram | Rexamel | Ruxpuram | Salopram | Samsung escitalopram | Sandoz escitalopram | Sarofram | Selopram | Serocover | Seropram | Sinsin escitalopram | Wi escitalopram | Yuapram</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Depralex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo escitalopram | Cipralex | Cipralex Meltz | Citoles | Escitalopram biogaran | Escitalopram normon | Esoplex | Esram | Mediprex | Pramacyt | Prylex | Zelax</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adescilan | Cipralex | Cipralex Meltz | Ciraset | Elicea | Escitalopram actavis | Escitalopram alvogen | Escitalopram Orion | Escitalopram Pharmaswiss | Escitalopram Portfarma | Escitalopram ranbaxy | Escitalopram ratiopharm | Escitalopram teva | Escitil | Eslorex | Estan | Nepanil | Norestal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Escitalopram eg | Escitalopram ratiopharm | Escitalopram sandoz | Sipralexa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adescilan | Cipralex | Despra | Elicea | Escitalopram Accord | Escitalopram actavis | Escitalopram alvogen | Escitalopram Orion | Escitalopram Portfarma | Escitalopram ratiopharm | Escitalopram teva | Escitil | Eslorex | Estan | Nepanil | Norestal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cilentra | Esciplex | Humorex | Loscita | S Citap | S Peram | Scipralex | Xetap</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aniavant | Asitalox | Bestrada | Bitalofar | Blusyver pro | Cravicem | Escitalopram | Escolam | Etalokare | Exaprem | Firsito | Klanasem | Lamobrigan | Lexapro | Lexcitox | Micropramcit | Nandresto | Obsyl | Paxtein | Pralex | Pramestar | Pratal | Precipra | Selective | Tavapride</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ajalopram | Deprilept | Elicea | Eslo | Esopam | Espran | Hovid escitalopram | Lexapro | Pramokline | Precipra</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Feliz s | Promedix escitalopram</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Escitalopram | Escitalopram Accord | Escitalopram actavis | Escitalopram Glenmark | Escitalopram mylan | Escitalopram ranbaxy | Escitalopram teva | Lexapro</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Cipralex Meltz | Escitalopram | Escitalopram bluefish | Escitalopram mylan | Escitalopram teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Escitalopram | Escitalopram apotex | Ethics escitalopram | Lexapro | Loxalate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clominil | Ecitalex | Escitalopram | Escitaspram | Esidep | Ezentius | Lexapro | Neopresol | Nexito | Selective</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Amantin | Anxipram | Anxipram 10 | Conjupram | Ecsapro | Escinal | Escivex | Esitalo | Excita | Exuber | Feliz s | Jovia | Lexapro | Lexdin | Mentumir | Morcet | Nexito | Ritemed escitalopram | S-celepra | Zescita | Zytapram</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">A calm | Ablixa | Anxifix | Anzmet | Arestalo | Atcopram | Avepram | Belexa | Cheer Up | Cibapram | Cipralex | Cironex | Citanew | Citanew D | Citapam | Danopram | Depram | Depsit | Despra | Detens | E cital | E Dynapram | E salpram | E-Pram | Ecit | Elexa | Es itopram | Es pramcit | Escadep | Escam | Esceto | Escilam | Esciret | Escitaur | Escosure | Esglit | Esitil | Eslopram | Eslopress | Espram | Essam | Esta | Estalogen | Estapram | Estar | Estex | Estiram | Estisave | Estly | Estopar | Estopram | Estram | Exapro | Exapro flash | Excita | Flotella | Gentle | Gerolin | Grip | Hapicit E | Healeez | Helixa | Hiacer | Itsal | Jespram | Joy | Kpram | Macescita | Macpram | Medpram | Mestom | Morcet | Neolexa | Neopram | Newam | Nomeset | Nuromec | Param | Pexnew | Pralex | Pramease | Pramis | Pramovo | Prevexa | Prodep | Prolex | Prolexa | Questa | Re-Uptol | Recita | Rize Plus | Rolax | S iso | S linear | Saipram | Selpram | Sensible | Seradep | Setak | Sitapram | Sn cit | Stelopam | Thymin | Tramalex | Ufrim | Zavesca | Zital</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aciprex | ApoEscitaxin | Betesda | Depralin | Deprilept | Elicea | Elicea q-tab | Escipram | Escitalopram actavis | Escitalopram Aurovitas | Escitalopram bluefish | Escitalopram Genoptim | Escitalopram Pharmaswiss | Escitalopram zdrovit | Escitasan | Escitil | Lenuxin | Lexapro | Mozarin | Mozarin Swift | Nexpram | Oroes | Pramatis | Savandra | Servenon | Symescital</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Escitalopram | Lexapro</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Entact | Escitalopram actavis | Escitalopram aurobindo | Escitalopram Azevedos | Escitalopram basi | Escitalopram bluefish | Escitalopram Bluepharma | Escitalopram ciclum | Escitalopram Cinfa | Escitalopram clamed | Escitalopram farmoz | Escitalopram Genedec | Escitalopram generis | Escitalopram Jaba | Escitalopram krka | Escitalopram Labesfal | Escitalopram leugim | Escitalopram mylan | Escitalopram pharmakern | Escitalopram ratiopharm | Escitalopram Tecnigen | Escitalopram tetrafarma | Escitalopram teva | Escitalopram Tolife | Escitalopram zentiva | Heipram</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Esc | Escitalopram seven | Ezentius | Novo humorap | Talopram</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Cipralex Meltz | Entapro | Exopex | Zelax</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Depresinal | Elicea | Elicea q-tab | Escitalopram actavis | Escitalopram atb | Escitalopram aurobindo | Escitalopram sandoz | Escitalopram teva | Escitalopram Torrent | Escitil | Eslorex | Estan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Eisipi | Elicea | Elicea q-tab | Escitalopram | Escitalopram alsi | Escitalopram canon | Escitalopram sandoz | Escitalopram sz | Escitalopram teva | Lenuxin | Miracetol | Selectra | Suncipam</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo escitalopram | Cipralex | Citoxal | Damesta | Depralex | Entapro | Escipra | Escitalax | Exopex | Pms escitalopram | Setapro | Zelax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Cipralex Meltz | Entact | Escitalopram Abacus Medicine | Escitalopram Accord | Escitalopram actavis | Escitalopram bluefish | Escitalopram ebb | Escitalopram Glenmark | Escitalopram krka | Escitalopram mylan | Escitalopram Orion | Escitalopram ranbaxy | Escitalopram sandoz | Escitalopram stada | Escitalopram teva | Premalex | Prilect | Seroplex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lepax | Lexapro</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Cipralex Meltz | Citafort | Ecytara | Eqores | Escitalopram teva | Solatcit</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cipralex | Despra | Elicea | Elicea q-tab | Escitalopram Accord | Escitalopram farmax | Escitalopram mylan | Escitalopram Orion | Escitalopram ratiopharm | Escitalopram teva | Escitalopram zentiva | Escitil | Esoprex | Isozyloram | Lenuxin | Miraklide | Solatcit</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Escitalopram sandoz | Esidep | Esopam | Feliz s | Lexapro | Valopram</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Esoprex | Mediprex | Purlex | Retabliss | S oropram | Scitoplex | Seroplex | Serotonyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anzyl | Avertyn | Cipralex | Citoles | Elitrex | Eslorex | Esmax | Esplus | Esram | Estilom | Exeram | Losiram | Loures | Secita | Sevpram | Sitela | Tiopram | Zendor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Citao s | Ec Pram | Escipro | Escitalo | Leeyo | Lepax | Lepram | Lexapro | Stalop | Talopram | Zydus escitalopram</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ciklox | Cipralex | Escitalopram | Escitalopram sandoz | Escitam 10 | Escitam 20 | Escitam acino | Essobel | Ezopram | Ezoprex | Feliz c | Giacintia | Recita-10 | Recita-5</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ec Pram</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aramix | Cipram S | E psiconor | E Zentius | E-Talpram | Escitalopram | Escitalopram Szabo | Servipax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">E Zentius | Escitalopram | Escitapax | Esprilex | Esynos | Ezentius | Ipran | Lexapro | Tasapan</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Ciramplex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord escitalopram | Aspen Escitalopram | Cipralex | Citraz | Dolin | Eprajub | Escitalopram unicorn | Escitalopram winthrop | Esetam | Felitor | Lexamil | Macleods escitalopram | Marprem | Mylan escitalopram | Nexito | Zitolex | Zydus escitalopram | Zytomil</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cilentra | Isolift</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ec Pram | Isolift</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21961502">
<a name="21961502"></a>Aigner M, Treasure J, Kaye W, Kasper S; WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. <i>World J Biol Psychiatry</i>. 2011;12(6):400-443. doi:10.3109/15622975.2011.602720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21961502/pubmed" id="21961502" target="_blank">21961502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27660499">
<a name="27660499"></a>AlQuorain S, Alfaraj S, Alshahrani M. Bilateral acute closed angle glaucoma associated with the discontinuation of escitalopram: a case report. <i>Open Access Emerg Med</i>. 2016;8:61-65. doi:10.2147/OAEM.S107551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27660499/pubmed" id="27660499" target="_blank">27660499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25356302">
<a name="25356302"></a>Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). <i>Sex Med</i>. 2014;2(2):60-90. doi:10.1002/sm2.28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25356302/pubmed" id="25356302" target="_blank">25356302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi: 10.2174/157488610789869265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd.pdf. Published November 2004. Accessed February 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2">
<a name="APA.2"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with obsessive-compulsive disorder. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd.pdf. Published July 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.3">
<a name="APA.3"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2nd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed August 16, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2019">
<a name="APA.2019"></a>American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf. Published February 16, 2019. Accessed December 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32777011">
<a name="32777011"></a>Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. <i>JAMA Psychiatry</i>. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32777011/pubmed" id="32777011" target="_blank">32777011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16584121">
<a name="16584121"></a>Areberg J, Christophersen JS, Poulsen MN, Larsen F, Molz KH. The pharmacokinetics of escitalopram in patients with hepatic impairment. <i>AAPS J</i>. 2006;8(1):E14-E19. doi:10.1208/aapsj080102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16584121/pubmed" id="16584121" target="_blank">16584121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36467010">
<a name="36467010"></a>Arshad H, Sana S, Sajnani PK, Owolabi O, Anand A. Escitalopram-induced akathisia in a patient with major depressive disorder: a rare case report. <i>SAGE Open Med Case Rep</i>. 2022;10:2050313X221139710. doi:10.1177/2050313X221139710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/36467010/pubmed" id="36467010" target="_blank">36467010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30885935">
<a name="30885935"></a>Assimon MM, Brookhart MA, Flythe JE. Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis<i>. J Am Soc Nephrol</i>. 2019;30(4):611-623. doi:10.1681/ASN.2018101032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30885935/pubmed" id="30885935" target="_blank">30885935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23699725">
<a name="23699725"></a>Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. <i>JAMA Intern Med</i>. 2013;173(12):1075-1081. doi:10.1001/jamainternmed.2013.714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23699725/pubmed" id="23699725" target="_blank">23699725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219059">
<a name="23219059"></a>Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. <i>J Affect Disord</i>. 2013;148(1):129-135. doi:10.1016/j.jad.2012.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23219059/pubmed" id="23219059" target="_blank">23219059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023a;24(2):79-117 doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023b;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385. doi:10.3109/15622975.2013.804195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, et al; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry.</i> 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29275963">
<a name="29275963"></a>Beach SR, Celano CM, Sugrue AM, et al. QT Prolongation, torsades de pointes, and psychotropic medications: a 5-year update. <i>Psychosomatics</i>. 2018;59(2):105-122. doi:10.1016/j.psym.2017.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29275963/pubmed" id="29275963" target="_blank">29275963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24922496">
<a name="24922496"></a>Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. <i>J Clin Psychiatry</i>. 2014;75(5):e441-e449. doi:10.4088/JCP.13r08672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24922496/pubmed" id="24922496" target="_blank">24922496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benedek.2009">
<a name="Benedek.2009"></a>Benedek DM, Friedman MJ, Zatzick D, Ursano RJ; American Psychiatric Association. Guideline watch (March 2009): practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd-watch.pdf. Published March 2009. Accessed July 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22299006">
<a name="22299006"></a>Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/22299006/pubmed" id="22299006" target="_blank">22299006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12715317">
<a name="12715317"></a>Bernard L, Stern R, Lew D, et al, “Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,” <i>Clin Infect Dis</i>, 2003, 36(9):1197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/12715317/pubmed" id="12715317" target="_blank">12715317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32135392">
<a name="32135392"></a>Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. <i>J Psychiatr Res</i>. 2020;124:99-108. doi:10.1016/j.jpsychires.2020.02.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32135392/pubmed" id="32135392" target="_blank">32135392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186-194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14719616">
<a name="14719616"></a>Bobo WV, Grammer GG. Escitalopram-associated mania. <i>Mil Med</i>. 2003;168(12):ii.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/14719616/pubmed" id="14719616" target="_blank">14719616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome [published correction appears in <i>N Engl J Med</i>. 2007;356(23):2437] [published correction appears in <i>N Engl J Med</i>. 2009;361(17):1714]. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30867630">
<a name="30867630"></a>Budzak LM, Yasin W, Mulhall J. Raising more than moods: escitalopram-associated priapism. <i>Fed Pract</i>. 2019;36(2):94-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30867630/pubmed" id="30867630" target="_blank">30867630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22480818">
<a name="22480818"></a>Carpenter JS, Guthrie KA, Larson JC, et al. Effect of escitalopram on hot flash interference: a randomized, controlled trial. <i>Fertil Steril.</i> 2012;97(6):1399-1404.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/22480818/pubmed" id="22480818" target="_blank">22480818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270-288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Casper.2018">
<a name="Casper.2018"></a>Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23360890">
<a name="23360890"></a>Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. <i>BMJ</i>. 2013;346:f288. doi:10.1136/bmj.f288<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23360890/pubmed" id="23360890" target="_blank">23360890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27135704">
<a name="27135704"></a>Chen HY, Lin CL, Lai SW, Kao CH. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. <i>J Clin Psychiatry</i>. 2016;77(6):e692-e696. doi:10.4088/JCP.15m10038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27135704/pubmed" id="27135704" target="_blank">27135704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23881712">
<a name="23881712"></a>Cheung AH, Kozloff N, Sacks D. Pediatric depression: an evidence-based update on treatment interventions. <i>Curr Psychiatry Rep</i>. 2013;15(8):381. doi:10.1007/s11920-013-0381-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23881712/pubmed" id="23881712" target="_blank">23881712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29483201">
<a name="29483201"></a>Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for adolescent depression in primary care (GLAD-PC): Part II. Treatment and ongoing management. <i>Pediatrics</i>. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29483201/pubmed" id="29483201" target="_blank">29483201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28342338">
<a name="28342338"></a>Chou PH, Chu CS, Chen YH, et al. Antidepressants and risk of cataract development: a population-based, nested case-control study. <i>J Affect Disord</i>. 2017;215:237-244. doi:10.1016/j.jad.2017.03.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28342338/pubmed" id="28342338" target="_blank">28342338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16841623">
<a name="16841623"></a>Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. <i>J Clin Psychiatry</i>. 2006;67(5):736-746. doi:10.4088/jcp.v67n0507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16841623/pubmed" id="16841623" target="_blank">16841623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause--2017 update. <i>Endocr Pract</i>. 2017;23(7):869-880. doi:10.4158/EP171828.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36540519">
<a name="36540519"></a>Conde SL, Nazha H, Simpkins C. Escitalopram induced angioedema. <i>Cureus</i>. 2022;14(11):e31600. doi:10.7759/cureus.31600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/36540519/pubmed" id="36540519" target="_blank">36540519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29463440">
<a name="29463440"></a>Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction?. <i>Sex Med Rev</i>. 2018;6(2):217-223. doi:10.1016/j.sxmr.2017.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29463440/pubmed" id="29463440" target="_blank">29463440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293-310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17202465">
<a name="17202465"></a>Covyeou JA, Jackson CW. Hyponatremia associated with escitalopram. <i>N Engl J Med</i>. 2007;356(1):94-95. doi:10.1056/NEJMc062840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17202465/pubmed" id="17202465" target="_blank">17202465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crone.2023">
<a name="Crone.2023"></a>Crone C, Fochtmann LJ, Attia E, et al; Guideline Writing Group<i>. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders</i>. 4th ed. American Psychiatric Association; 2023. doi:10.1176/appi.books.9780890424865</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crow.2019">
<a name="Crow.2019"></a>Crow SJ. Bulimia nervosa in adults: Pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19716436">
<a name="19716436"></a>Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. <i>Clin Gastroenterol Hepatol</i>. 2009;7(12):1314-1321. doi:10.1016/j.cgh.2009.08.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19716436/pubmed" id="19716436" target="_blank">19716436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24847997">
<a name="24847997"></a>De Berardis D, Serroni N, Marini S, et al. Emerging mania following escitalopram withdrawal in a patient with unipolar depression managed with its reintroduction. <i>J Psychiatr Pract</i>. 2014;20(3):228-231. doi:10.1097/01.pra.0000450323.37038.a9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24847997/pubmed" id="24847997" target="_blank">24847997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi:10.1016/j.psym.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19439155">
<a name="19439155"></a>Defronzo Dobkin R, Menza M, Allen LA, et al, "Escitalopram Reduces Hot Flashes in Nondepressed Menopausal Women: A Pilot Study," <i>Ann Clin Psychiatry</i>, 2009, 21(2):70-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19439155/pubmed" id="19439155" target="_blank">19439155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29651785">
<a name="29651785"></a>Delaney SR, Malik PRV, Stefan C, Edginton AN, Colantonio DA, Ito S. Predicting escitalopram exposure to breastfeeding infants: integrating analytical and in silico techniques. <i>Clin Pharmacokinet</i>. 2018;57(12):1603-1611. doi:10.1007/s40262-018-0657-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29651785/pubmed" id="29651785" target="_blank">29651785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31577402">
<a name="31577402"></a>
<i>Depression in children and young people: identification and management</i>. London: National Institute for Health and Care Excellence (NICE) (UK); June 25, 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/31577402/pubmed" id="31577402" target="_blank">31577402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536379">
<a name="29536379"></a>Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. <i>CNS Drugs</i>. 2018;32(4):321-334. doi:10.1007/s40263-018-0507-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29536379/pubmed" id="29536379" target="_blank">29536379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28784915">
<a name="28784915"></a>Dy P, Arcega V, Ghali W, Wolfe W. Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan. <i>BMJ Case Rep</i>. 2017;2017:bcr2017221486. doi:10.1136/bcr-2017-221486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28784915/pubmed" id="28784915" target="_blank">28784915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24631758">
<a name="24631758"></a>Erie JC, Brue SM, Chamberlain AM, Hodge DO. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. <i>Am J Ophthalmol</i>. 2014;158(1):192-197.e1. doi:10.1016/j.ajo.2014.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24631758/pubmed" id="24631758" target="_blank">24631758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18344730">
<a name="18344730"></a>Eriksson E, Ekman A, Sinclair S, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. <i>J Clin Psychopharmacol.</i> 2008;28(2):195-202. doi:10.1097/JCP.0b013e3181678a28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18344730/pubmed" id="18344730" target="_blank">18344730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amneal.1">
<a name="Amneal.1"></a>Escitalopram [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.1">
<a name="Lannett.1"></a>Escitalopram Oxalate oral solution [prescribing information]. Philadelphia, PA: Lannett Company Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28763345">
<a name="28763345"></a>Etminan M, Sodhi M, Procyshyn RM, Guo M, Carleton BC. Risk of hair loss with different antidepressants: a comparative retrospective cohort study. <i>Int Clin Psychopharmacol</i>. 2018;33(1):44-48. doi:10.1097/YIC.0000000000000191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28763345/pubmed" id="28763345" target="_blank">28763345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Export.DOR">
<a name="Export.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721705">
<a name="25721705"></a>Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. <i>Psychother Psychosom</i>. 2015;84(2):72-81. doi:10.1159/000370338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25721705/pubmed" id="25721705" target="_blank">25721705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683858">
<a name="16683858"></a>Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16683858/pubmed" id="16683858" target="_blank">16683858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621834">
<a name="19621834"></a>Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2009;80(3):239-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19621834/pubmed" id="19621834" target="_blank">19621834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17240120">
<a name="17240120"></a>Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents relapse of obsessive-compulsive disorder. <i>Eur Neuropsychopharmacol.</i> 2007;17(6-7):430-439. doi: 10.1016/j.euroneuro.2006.11.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17240120/pubmed" id="17240120" target="_blank">17240120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33136924">
<a name="33136924"></a>Fischer A, Connor AT, Machenzie KM, Shaw RJ. Selective serotonin reuptake inhibitors and tardive dyskinesia: a case report of escitalopram use in a cardiac and liver transplant patient. <i>J Clin Psychopharmacol</i>. 2020;40(6):626-627. doi:10.1097/JCP.0000000000001285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/33136924/pubmed" id="33136924" target="_blank">33136924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31648376">
<a name="31648376"></a>Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. <i>Acta Psychiatr Scand</i>. 2020;141(1):21-33. doi:10.1111/acps.13120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/31648376/pubmed" id="31648376" target="_blank">31648376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21245182">
<a name="21245182"></a>Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. <i>JAMA.</i> 2011;305(3):267-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21245182/pubmed" id="21245182" target="_blank">21245182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15960573">
<a name="15960573"></a>Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. <i>J Clin Psychiatry.</i> 2005;66(6):769-773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15960573/pubmed" id="15960573" target="_blank">15960573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259697">
<a name="24259697"></a>Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. <i>Ann Pharmacother</i>. 2013;47(10):1330-1341. doi:10.1177/1060028013501994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24259697/pubmed" id="24259697" target="_blank">24259697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27773479">
<a name="27773479"></a>Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-generation antidepressants and hyponatremia risk: a population-based cohort study of older adults. <i>Am J Kidney Dis</i>. 2017;69(1):87-96. doi:10.1053/j.ajkd.2016.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27773479/pubmed" id="27773479" target="_blank">27773479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193145">
<a name="22193145"></a>Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Wood DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause: executive summary of recommendations. <i>Endocr Pract</i>. 2011;17(6):949-954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/22193145/pubmed" id="22193145" target="_blank">22193145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243609">
<a name="12243609"></a>Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. <i>Ann Pharmacother</i>. 2002;36(10):1577-1589. doi:10.1345/aph.1A195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/12243609/pubmed" id="12243609" target="_blank">12243609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17239054">
<a name="17239054"></a>Grover S, Biswas P, Bhateja G, Kulhara P. Escitalopram-associated hyponatremia. <i>Psychiatry Clin Neurosci</i>. 2007;61(1):132-133. doi:10.1111/j.1440-1819.2007.01625.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17239054/pubmed" id="17239054" target="_blank">17239054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522259">
<a name="29522259"></a>Grzeskowiak LE, Leggett C, Costi L, Roberts CT, Amir LH. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. <i>Br J Clin Pharmacol</i>. 2018;84(6):1373-1379. doi:10.1111/bcp.13575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29522259/pubmed" id="29522259" target="_blank">29522259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18058852">
<a name="18058852"></a>Guerdjikova AI, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. <i>Hum Psychopharmacol.</i> 2008;23(1):1-11. doi:10.1002/hup.899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18058852/pubmed" id="18058852" target="_blank">18058852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337001">
<a name="29337001"></a>Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? <i>Curr Probl Pediatr Adolesc Health Care</i>. 2018;48(2):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29337001/pubmed" id="29337001" target="_blank">29337001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28577352">
<a name="28577352"></a>Heller HM, Ravelli ACJ, Bruning AHL, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. <i>BMC Pregnancy Childbirth</i>. 2017;17(1):166. doi:10.1186/s12884-017-1334-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28577352/pubmed" id="28577352" target="_blank">28577352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019">
<a name="Hirsch.2019"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 28, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2">
<a name="Hirsch.2"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9 2021c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15046541">
<a name="15046541"></a>Hirschfeld RM, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. <i>J Clin Psychiatry</i>. 2004;65 Suppl 4:46-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15046541/pubmed" id="15046541" target="_blank">15046541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21926427">
<a name="21926427"></a>Huezo-Diaz, P, Perroud N, Spencer EP, et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. <i>J Psychopharmacol</i>. 2012;26(3):398-407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21926427/pubmed" id="21926427" target="_blank">21926427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17426664">
<a name="17426664"></a>Huska MT, Catalano G, Catalano MC. Serotonin syndrome associated with the use of escitalopram. <i>CNS Spectr</i>. 2007;12(4):270-274. doi:10.1017/s1092852900021027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17426664/pubmed" id="17426664" target="_blank">17426664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27378473">
<a name="27378473"></a>Ismaili E, Walsh S, O'Brien PMS, et al; Consensus Group of the International Society for Premenstrual Disorders. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. <i>Arch Womens Ment Health. </i>2016;19(6):953-958. doi:10.1007/s00737-016-0631-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27378473/pubmed" id="27378473" target="_blank">27378473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18315447">
<a name="18315447"></a>Isolan L, Pheula G, Salum GA Jr, et al. An open-label trial of escitalopram in children and adolescents with social anxiety disorder. <i>J Child Adolesc Psychopharmacol</i>. 2007;17(6):751-760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18315447/pubmed" id="18315447" target="_blank">18315447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27249090">
<a name="27249090"></a>Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. <i>J Clin Psychiatry.</i> 2016;77(5):e605-e611. doi:10.4088/JCP.14r09758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27249090/pubmed" id="27249090" target="_blank">27249090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618-1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24314591">
<a name="24314591"></a>Jeong BO, Kim SW, Kim SY, Kim JM, Shin IS, Yoon JS. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. <i>Psychosomatics</i>. 2014;55(3):213-220. doi:10.1016/j.psym.2013.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24314591/pubmed" id="24314591" target="_blank">24314591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955469">
<a name="29955469"></a>Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. <i>Ment Health Clin</i>. 2016;6(4):191-196. doi:10.9740/mhc.2016.07.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29955469/pubmed" id="29955469" target="_blank">29955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9681666">
<a name="9681666"></a>Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jørgensen T, Sidhu J. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. <i>Eur J Clin Pharmacol</i>. 1998;54(3):237-242. doi:10.1007/s002280050452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/9681666/pubmed" id="9681666" target="_blank">9681666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15738503">
<a name="15738503"></a>Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. <i>Br J Psychiatry.</i> 2005;186:222-226. doi:10.1192/bjp.186.3.222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15738503/pubmed" id="15738503" target="_blank">15738503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247774">
<a name="30247774"></a>Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis. <i>Int J Geriatr Psychiatry</i>. 2018;33(12):1688-1708. doi:10.1002/gps.4974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30247774/pubmed" id="30247774" target="_blank">30247774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khera.1">
<a name="Khera.1"></a>Khera M, Cunningham GR. Treatment of male sexual dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20177584">
<a name="20177584"></a>Kumar D, Saaraswat T, Sengupta SN, Mehrotra S. Upper gastrointestinal bleeding in a patient with depression receiving selective serotonin reuptake inhibitor therapy. <i>Indian J Pharmacol</i>. 2009;41(1):51-53. doi:10.4103/0253-7613.48881<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/20177584/pubmed" id="20177584" target="_blank">20177584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33425536">
<a name="33425536"></a>Kumar S, Gayle JA, Mogalapalli A, Hussain ST, Castiglioni A. Escitalopram induced torsade de pointes and cardiac arrest in a patient with surgically treated mitral valve prolapse. <i>Cureus</i>. 2020;12(12):e11960. doi:10.7759/cureus.11960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/33425536/pubmed" id="33425536" target="_blank">33425536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948719">
<a name="21948719"></a>Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. <i>CMAJ</i>. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21948719/pubmed" id="21948719" target="_blank">21948719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15274173">
<a name="15274173"></a>Lader M, Stender K, Bürger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. <i>Depress Anxiety</i>. 2004;19(4):241-248. doi:10.1002/da.20014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15274173/pubmed" id="15274173" target="_blank">15274173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10755580">
<a name="10755580"></a>Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. <i>J Child Adolesc Psychopharmacol</i>. 2000;10(1):35-38. doi:10.1089/cap.2000.10.35<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/10755580/pubmed" id="10755580" target="_blank">10755580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23422053">
<a name="23422053"></a>Lam RW. Antidepressants and QTc prolongation. <i>J Psychiatry Neurosci</i>. 2013;38(2):E5-E6. doi:10.1503/jpn.120256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23422053/pubmed" id="23422053" target="_blank">23422053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31078196">
<a name="31078196"></a>Lanza di Scalea T, Pearlstein T. Premenstrual dysphoric disorder. <i>Med Clin North Am</i>. 2019;103(4):613-628. doi:10.1016/j.mcna.2019.02.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/31078196/pubmed" id="31078196" target="_blank">31078196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.1">
<a name="Allergan.1"></a>Lexapro (escitalopram) [prescribing information]. North Chicago, IL: Abbvie Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.1">
<a name="Allergan.1"></a>Lexapro (escitalopram) [prescribing information]. North Chicago, IL: Abbvie Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8804257">
<a name="8804257"></a>Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports [published correction appears in Can Med Assoc J 1996 Oct 15;155(8):1043]. <i>CMAJ</i>. 1996;155(5):519-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/8804257/pubmed" id="8804257" target="_blank">8804257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17919277">
<a name="17919277"></a>Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. <i>Aliment Pharmacol Ther</i>. 2008;27(1):31-40. doi:10.1111/j.1365-2036.2007.03541.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17919277/pubmed" id="17919277" target="_blank">17919277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16390902">
<a name="16390902"></a>Loughhead AM, Fisher AD, Newport DJ, et al. Antidepressants in amniotic fluid: another route of fetal exposure. <i>Am J Psychiatry</i>. 2006;163(1):145-147. doi:10.1176/appi.ajp.163.1.145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16390902/pubmed" id="16390902" target="_blank">16390902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31318184">
<a name="31318184"></a>Madsen T, Buttenschøn HN, Uher R, et al. Trajectories of suicidal ideation during 12 weeks of escitalopram or nortriptyline antidepressant treatment among 811 patients with major depressive disorder. <i>J Clin Psychiatry</i>. 2019;80(4):18m12575. doi:10.4088/JCP.18m12575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/31318184/pubmed" id="31318184" target="_blank">31318184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mahlberg.1">
<a name="Mahlberg.1"></a>Mahlberg R, Kunz D, Sasse J, et al, “Serotonin Syndrome With Tramadol and Citalopram,” <i>Am J Psychiatry</i>, 2004, 161(6):1129.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19965920">
<a name="19965920"></a>Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. <i>J Clin Endocrinol Metab</i>. 2010;95(2):837-846. doi:10.1210/jc.2009-1575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19965920/pubmed" id="19965920" target="_blank">19965920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30170040">
<a name="30170040"></a>Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. <i>Am J Obstet Gynecol</i>. 2019;220(1):57.e1-57.e13. doi:10.1016/j.ajog.2018.08.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30170040/pubmed" id="30170040" target="_blank">30170040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25248846">
<a name="25248846"></a>Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clin Pharmacokinet</i>. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25248846/pubmed" id="25248846" target="_blank">25248846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” <i>Chest</i>, 2003, 123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11393591">
<a name="11393591"></a>Montgomery SA, Loft H, Sanchez C, et al, “Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted From a Rat Model,” <i>Pharmacol Toxicol</i>, 2001, 88(5):282-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/11393591/pubmed" id="11393591" target="_blank">11393591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14581256">
<a name="14581256"></a>Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. <i>Arch Intern Med</i>. 2003;163(19):2354-2358. doi:10.1001/archinte.163.19.2354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/14581256/pubmed" id="14581256" target="_blank">14581256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16266205">
<a name="16266205"></a>Murdoch D and Keam SJ, "Escitalopram: A Review of Its Use in the Management of Major Depressive Disorder," <i>Drugs</i>, 2005, 65(16):2379-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16266205/pubmed" id="16266205" target="_blank">16266205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859791">
<a name="22859791"></a>Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). <i>Nephrol Dial Transplant</i>. 2012;27(10):3736-3745. doi:10.1093/ndt/gfs295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/22859791/pubmed" id="22859791" target="_blank">22859791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21453380">
<a name="21453380"></a>Nelson JC and Devanand DP, "A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia," <i>J Am Geriatr Soc</i>, 2011, 59(4):577-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21453380/pubmed" id="21453380" target="_blank">21453380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23624686">
<a name="23624686"></a>Nevatte T, O'Brien PM, Bäckström T, et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. <i>Arch Womens Ment Health</i>. 2013;16(4):279-291. doi:10.1007/s00737-013-0346-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23624686/pubmed" id="23624686" target="_blank">23624686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30407100">
<a name="30407100"></a>Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. <i>J Womens Health (Larchmt)</i>. 2019;28(3):331-338. doi:10.1089/jwh.2018.7319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30407100/pubmed" id="30407100" target="_blank">30407100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26382310">
<a name="26382310"></a>North American Menopause Society (NAMS). Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. <i>Menopause</i>. 2015;22(11):1155-1172. doi:10.1097/GME.0000000000000546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26382310/pubmed" id="26382310" target="_blank">26382310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37252752">
<a name="37252752"></a>North American Menopause Society 2023 Nonhormone Therapy Position Statement Advisory Panel. The 2023 nonhormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2023;30(6):573-590. doi:10.1097/GME.0000000000002200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/37252752/pubmed" id="37252752" target="_blank">37252752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract.</i> 2013;26(4):389-396. doi:10.1177/0897190012467210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460039">
<a name="18460039"></a>Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. <i>Br J Clin Pharmacol</i>. 2008;66(1):76-81. doi:10.1111/j.1365-2125.2008.03154.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18460039/pubmed" id="18460039" target="_blank">18460039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25572308">
<a name="25572308"></a>Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. <i>Hum Psychopharmacol</i>. 2015;30(1):4-20. doi:10.1002/hup.2451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25572308/pubmed" id="25572308" target="_blank">25572308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15156966">
<a name="15156966"></a>Pass SE and Simpson RW, “Discontinuation and Reinstitution of Medications During the Perioperative Period,” <i>Am J Health Syst Pharm</i>, 2004, 61(9):899-912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15156966/pubmed" id="15156966" target="_blank">15156966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26667012">
<a name="26667012"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open</i>. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26667012/pubmed" id="26667012" target="_blank">26667012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30090797">
<a name="30090797"></a>Pathania M, Goel B, Dhamija P, Kant R, Dhar M, Mittal S. A rare adverse drug reaction to escitalopram. <i>J Family Med Prim Care</i>. 2018;7(2):466-467. doi:10.4103/jfmpc.jfmpc_105_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30090797/pubmed" id="30090797" target="_blank">30090797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phillips.1">
<a name="Phillips.1"></a>Phillips KA. Body dysmorphic disorder: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 16, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18325859">
<a name="18325859"></a>Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. <i>Body Image</i>. 2008;5(1):13-27. doi:10.1016/j.bodyim.2007.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18325859/pubmed" id="18325859" target="_blank">18325859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27056606">
<a name="27056606"></a>Phillips KA, Keshaviah A, Dougherty DD, et al. Pharmacotherapy relapse prevention in body dysmorphic disorder: a double-blind, placebo-controlled trial. <i>Am J Psychiatry.</i> 2016;173(9):887-895. doi:10.1176/appi.ajp.2016.15091243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27056606/pubmed" id="27056606" target="_blank">27056606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15504660">
<a name="15504660"></a>Prapotnik M, Di Pauli J, Vetter Z, König P, Conca A, Waschgler R. Antidepressant-associated mania with escitalopram. <i>Eur Psychiatry</i>. 2004;19(7):455-456. doi:10.1016/j.eurpsy.2004.06.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15504660/pubmed" id="15504660" target="_blank">15504660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27977469">
<a name="27977469"></a>Qi W, Gevonden M, Shalev A. Efficacy and tolerability of high-dose escitalopram in posttraumatic stress disorder.<i> J Clin Psychopharmacol.</i> 2017;37(1):89-93. doi:10.1097/JCP.0000000000000626<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27977469/pubmed" id="27977469" target="_blank">27977469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18090508">
<a name="18090508"></a>Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. <i>Int Clin Psychopharmacol</i>. 2008;23(1):49-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18090508/pubmed" id="18090508" target="_blank">18090508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18340692">
<a name="18340692"></a>Rabins PV, Blacker D, Rovner BW, et al, “American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,” <i>Am J Psychiatry</i>, 2007, 164(12 Suppl):5-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18340692/pubmed" id="18340692" target="_blank">18340692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30254775">
<a name="30254775"></a>Raj R, Jacob A, Venkatanarayan A, Doraiswamy M, Ashok M. Severe symptomatic hyponatremia secondary to escitalopram-induced SIADH: a case report with literature review. <i>Case Rep Nephrol</i>. 2018;2018:3697120. doi:10.1155/2018/3697120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30254775/pubmed" id="30254775" target="_blank">30254775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415709">
<a name="16415709"></a>Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I. New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. <i>J Clin Psychopharmacol</i>. 2006;26(1):67-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16415709/pubmed" id="16415709" target="_blank">16415709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16934048">
<a name="16934048"></a>Rampono J, Hackett LP, Kristensen JH, et al. Transfer of escitalopram and its metabolite demethylescitalopram into breast milk. <i>Br J Clin Pharmacol.</i> 2006;62(3):316-322. doi:10.1111/j.1365-2125.2006.02659.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16934048/pubmed" id="16934048" target="_blank">16934048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19452377">
<a name="19452377"></a>Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. <i>Pharmacopsychiatry</i>. 2009;42(3):95-100. doi:10.1055/s-0028-1103296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19452377/pubmed" id="19452377" target="_blank">19452377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17375980">
<a name="17375980"></a>Rao N, "The Clinical Pharmacokinetics of Escitalopram," <i>Clin Pharmacokinet</i>, 2007, 46(4):281-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17375980/pubmed" id="17375980" target="_blank">17375980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29302568">
<a name="29302568"></a>Rawal G, Kumar R, Yadav S. Severe hyponatremia associated with escitalopram. <i>J Family Med Prim Care</i>. 2017;6(2):453-454. doi:10.4103/2249-4863.220043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29302568/pubmed" id="29302568" target="_blank">29302568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26156519">
<a name="26156519"></a>Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; National Birth Defects Prevention Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. <i>BMJ</i>. 2015;351:h3190. doi:10.1136/bmj.h3190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26156519/pubmed" id="26156519" target="_blank">26156519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23596418">
<a name="23596418"></a>Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. <i>Front Pharmacol</i>. 2013;4:45. doi:10.3389/fphar.2013.00045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23596418/pubmed" id="23596418" target="_blank">23596418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242321">
<a name="17242321"></a>Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. <i>Arch Intern Med</i>. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17242321/pubmed" id="17242321" target="_blank">17242321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17107242">
<a name="17107242"></a>Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. <i>J Clin Psychiatry</i>. 2006;67(10):1522-1526. doi:10.4088/jcp.v67n1005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17107242/pubmed" id="17107242" target="_blank">17107242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32048624">
<a name="32048624"></a>Roy P, Gupta B, Tripathi A, Nischal A, Dalal PK, Kar SK. Sexual functioning in females with depression in remission receiving escitalopram. <i>Indian J Med Res</i>. 2019;150(6):606-611. doi:10.4103/ijmr.IJMR_1991_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32048624/pubmed" id="32048624" target="_blank">32048624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26644543">
<a name="26644543"></a>Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. <i>J Clin Oncol</i>. 2016;34(6):611-635. doi: 10.1200/JCO.2015.64.3809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26644543/pubmed" id="26644543" target="_blank">26644543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-e809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553536">
<a name="16553536"></a>Safer DJ and Zito JM, "Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,” <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(1-2):159-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16553536/pubmed" id="16553536" target="_blank">16553536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27834194">
<a name="27834194"></a>Samuel NG, Seifert CF. Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. <i>Ann Pharmacother</i>. 2017;51(3):226-231. doi:10.1177/1060028016677309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27834194/pubmed" id="27834194" target="_blank">27834194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21189920">
<a name="21189920"></a>Sanyal D, Chakraborty S, Bhattacharyya R. An interesting case of serotonin syndrome precipitated by escitalopram. <i>Indian J Pharmacol</i>. 2010;42(6):418-419. doi:10.4103/0253-7613.71899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21189920/pubmed" id="21189920" target="_blank">21189920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26491328">
<a name="26491328"></a>Sato Y, Nakamura K, Yasui-Furukori N. Serotonin syndrome induced by the readministration of escitalopram after a short-term interruption in an elderly woman with depression: a case report. <i>Neuropsychiatr Dis Treat</i>. 2015;11:2505-2507. doi:10.2147/NDT.S92081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26491328/pubmed" id="26491328" target="_blank">26491328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32238008">
<a name="32238008"></a>Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opin Drug Metab Toxicol</i>. 2020;16(5):431-440. doi:10.1080/17425255.2020.1750598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32238008/pubmed" id="32238008" target="_blank">32238008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28197332">
<a name="28197332"></a>Selvaraj V, Hour S, Gunasekar P, Gray C, Smith JF. Escitalopram-induced amenorrhea and false positive urine pregnancy test. <i>Korean J Fam Med</i>. 2017;38(1):40-42. doi:10.4082/kjfm.2017.38.1.40<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28197332/pubmed" id="28197332" target="_blank">28197332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sharma.2009">
<a name="Sharma.2009"></a>Sharma RC. Escitalopram-induced subconjunctival hemorrhage: a case report. <i>Primary Psychiatry</i>. 2009;16(7):29-30.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19629025">
<a name="19629025"></a>Sharma RC. Hypomania induced by escitalopram: 2 case reports. <i>Psychopharmacol Bull</i>. 2009;42(2):89-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19629025/pubmed" id="19629025" target="_blank">19629025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21829108">
<a name="21829108"></a>Shim G, Park HY, Jang JH, et al. What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study. <i>Int Clin Psychopharmacol.</i> 2011;26(5):284-290. doi:10.1097/YIC.0b013e32834a5c09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21829108/pubmed" id="21829108" target="_blank">21829108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34961344">
<a name="34961344"></a>Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. <i>J Urol</i>. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/34961344/pubmed" id="34961344" target="_blank">34961344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21824458">
<a name="21824458"></a>Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. <i>J Clin Psychiatry</i>. 2011;72(7):994-1001. doi:10.4088/JCP.10m06461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21824458/pubmed" id="21824458" target="_blank">21824458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31035856">
<a name="31035856"></a>Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. <i>Womens Health (Lond)</i>. 2019;15:1745506519844044. doi:10.1177/1745506519844044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/31035856/pubmed" id="31035856" target="_blank">31035856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30964616">
<a name="30964616"></a>Sobieraj DM, Baker WL, Martinez BK, et al. <i>Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults</i>. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30964616/pubmed" id="30964616" target="_blank">30964616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16291715">
<a name="16291715"></a>Søgaard B, Mengel H, Rao N, et al, “The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects,” <i>J Clin Pharmacol</i>, 2005, 45(12):1400-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16291715/pubmed" id="16291715" target="_blank">16291715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11214779">
<a name="11214779"></a>Spigset O, Hägg S, Stegmayr B, Dahlqvist R. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. <i>Eur J Clin Pharmacol</i>. 2000;56(9-10):699-703. doi:10.1007/s002280000205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/11214779/pubmed" id="11214779" target="_blank">11214779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14658946">
<a name="14658946"></a>Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. <i>J Clin Psychiatry</i>. 2003;64(11):1322-1327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/14658946/pubmed" id="14658946" target="_blank">14658946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10333979">
<a name="10333979"></a>Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>J Affect Disord</i>. 1998;51(3):215-235. doi:10.1016/s0165-0327(98)00221-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/10333979/pubmed" id="10333979" target="_blank">10333979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17407626">
<a name="17407626"></a>Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. <i>Curr Med Res Opin.</i> 2007;23(4):701-711. doi:10.1185/030079907X178838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17407626/pubmed" id="17407626" target="_blank">17407626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.1">
<a name="Stein.1"></a>Stein MB, Goin MK, Pollac MH, et al; American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. 2009. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed March 11, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32857933">
<a name="32857933"></a>Strawn JR, Mills JA, Schroeder H, et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. <i>J Clin Psychiatry</i>. 2020;81(5):20m13396. doi:10.4088/JCP.20m13396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32857933/pubmed" id="32857933" target="_blank">32857933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27004312">
<a name="27004312"></a>Suphanklang J, Santimaleeworagun W, Supasyndh O. Combination of escitalopram and rasagiline induced serotonin syndrome: a case report and review literature. <i>J Med Assoc Thai</i>. 2015;98(12):1254-1257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27004312/pubmed" id="27004312" target="_blank">27004312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30844852">
<a name="30844852"></a>Suzuki A, Otani K. Serotonin syndrome after an alcohol intake in a patient treated with escitalopram and clomipramine. <i>Clin Neuropharmacol</i>. 2019;42(3):103-104. doi:10.1097/WNF.0000000000000331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30844852/pubmed" id="30844852" target="_blank">30844852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14984623">
<a name="14984623"></a>Tahir N. Serotonin Syndrome as a Consequence of Drug-Resistant Infections: An Interaction Between Linezolid and Citalopram. <i>J Am Med Dir Assoc</i>. 2004;5(2):111-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/14984623/pubmed" id="14984623" target="_blank">14984623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25619672">
<a name="25619672"></a>Tampi RR, Balderas M, Carter KV, et al. Citalopram, QTc prolongation, and torsades de pointes. <i>Psychosomatics</i>. 2015;56(1):36-43. doi:10.1016/j.psym.2014.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/25619672/pubmed" id="25619672" target="_blank">25619672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19491861">
<a name="19491861"></a>Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2009;104(6):1475-1482. doi:10.1038/ajg.2009.128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19491861/pubmed" id="19491861" target="_blank">19491861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17088502">
<a name="17088502"></a>Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63(11):1217-23. doi:10.1001/archpsyc.63.11.1217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17088502/pubmed" id="17088502" target="_blank">17088502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23928296">
<a name="23928296"></a>Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. <i>Eur Neuropsychopharmacol</i>. 2013;23(11):1391-1400. doi:10.1016/j.euroneuro.2013.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23928296/pubmed" id="23928296" target="_blank">23928296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57]. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(6):981]. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi: 10.1161/CIR.0000000000000905.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28766108">
<a name="28766108"></a>Tomlin AM, Reith DM, Woods DJ, et al. A pharmacoepidemiology database system for monitoring risk due to the use of medicines by New Zealand primary care patients. <i>Drug Saf</i>. 2017;40(12):1259-1277. doi:10.1007/s40264-017-0579-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28766108/pubmed" id="28766108" target="_blank">28766108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20350136">
<a name="20350136"></a>Tsai MH, Lin KM, Hsiao MC, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. <i>Pharmacogenomics</i>. 2010;11(4):537-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/20350136/pubmed" id="20350136" target="_blank">20350136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22133983">
<a name="22133983"></a>Tseng PT, Lee Y, Lin YE, et al, “Low-Dose Escitalopram for 2 Days Associated With Corrected QT Interval Prolongation in a Middle-Aged Woman: A Case Report and Literature Review,” <i>Gen Hosp Psychiatry</i>, 2012, 34(2):210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/22133983/pubmed" id="22133983" target="_blank">22133983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ursano.2004">
<a name="Ursano.2004"></a>Ursano RJ, Bell C, Eth S, et al; Work Group on ASD and PTSD. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd.pdf. Published November 2004. Accessed July 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VaDoD.1">
<a name="VaDoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf</a>. Updated February 2022. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906018">
<a name="15906018"></a>van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. <i>Eur J Clin Pharmacol</i>. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15906018/pubmed" id="15906018" target="_blank">15906018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27663940">
<a name="27663940"></a>Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2016;55(10):851-859.e2. doi:10.1016/j.jaac.2016.07.768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/27663940/pubmed" id="27663940" target="_blank">27663940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18219438">
<a name="18219438"></a>Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. <i>Calcif Tissue Int</i>. 2008;82(2):92-101. doi: 10.1007/s00223-007-9099-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/18219438/pubmed" id="18219438" target="_blank">18219438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11454728">
<a name="11454728"></a>Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-Citalopram) and its Metabolites <i>in vitro</i>: Cytochromes Mediating Biotransformation, Inhibitory Effects, and Comparison to R-Citalopram. <i>Drug Metab Dispos</i>, 2001, 29(8):1102-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/11454728/pubmed" id="11454728" target="_blank">11454728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35434055">
<a name="35434055"></a>Wabont G, Ferret L, Houdre N, Lepied A, Bene J, Cousein E. Escitalopram-induced hepatitis: a case report. <i>World J Clin Cases</i>. 2022;10(8):2468-2473. doi:10.12998/wjcc.v10.i8.2468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/35434055/pubmed" id="35434055" target="_blank">35434055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21410960">
<a name="21410960"></a>Wade AG, Crawford GM, Yellowlees A. Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in major depressive disorder (MDD): an open-label, pilot study.<i> BMC Psychiatry.</i> 2011;11:42. doi: 10.1186/1471-244X-11-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/21410960/pubmed" id="21410960" target="_blank">21410960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia</i>. 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26003261">
<a name="26003261"></a>Waldinger MD. Psychiatric disorders and sexual dysfunction. <i>Handb Clin Neurol</i>. 2015;130:469-489. doi:10.1016/B978-0-444-63247-0.00027-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/26003261/pubmed" id="26003261" target="_blank">26003261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439401">
<a name="32439401"></a>Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32439401/pubmed" id="32439401" target="_blank">32439401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32162723">
<a name="32162723"></a>Weisskopf E, Guidi M, Fischer CJ, et al. A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: prediction of infant drug exposure through breast milk. <i>Br J Clin Pharmacol</i>. 2020;86(8):1642-1653. doi:10.1111/bcp.14278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/32162723/pubmed" id="32162723" target="_blank">32162723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169695">
<a name="15169695"></a>Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. <i>Am J Psychiatry.</i> 2004;161(6):1066-1078. doi: 10.1176/appi.ajp.161.6.1066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/15169695/pubmed" id="15169695" target="_blank">15169695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953843">
<a name="28953843"></a>Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. <i>Psychiatr Danub</i>. 2017;29(suppl 3):629-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/28953843/pubmed" id="28953843" target="_blank">28953843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35475053">
<a name="35475053"></a>Yadav A, Bharat BS, Montrose S. Abnormal uterine bleed in a postmenopausal woman with the use of escitalopram. <i>Cureus</i>. 2022;14(3):e23432. doi:10.7759/cureus.23432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/35475053/pubmed" id="35475053" target="_blank">35475053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30147322">
<a name="30147322"></a>Yamaguchi Y, Kimoto S, Nagahama T, Kishimoto T. Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series. <i>Neuropsychiatr Dis Treat</i>. 2018;14:2099-2104. doi:10.2147/NDT.S168078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/30147322/pubmed" id="30147322" target="_blank">30147322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20170390">
<a name="20170390"></a>Yilmaz Z, Ceschi A, Rauber-Lüthy C, et al. Escitalopram causes fewer seizures in human overdose than citalopram. <i>Clin Toxicol (Phila)</i>. 2010;48(3):207-212. doi:10.3109/15563650903585937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/20170390/pubmed" id="20170390" target="_blank">20170390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et al, “The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,” <i>Obstet Gynecol</i>, 2009, 114(3):703-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16765693">
<a name="16765693"></a>Zelefsky JR, Fine HF, Rubinstein VJ, Hsu IS, Finger PT. Escitalopram-induced uveal effusions and bilateral angle closure glaucoma. <i>Am J Ophthalmol</i>. 2006;141(6):1144-1147. doi:10.1016/j.ajo.2006.01.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/escitalopram-drug-information/abstract-text/16765693/pubmed" id="16765693" target="_blank">16765693</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9046 Version 653.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
